{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,24]],"date-time":"2026-10-24T00:27:06Z","timestamp":1792801626146,"version":"4.5.0"},"reference-count":304,"publisher":"MDPI AG","issue":"6","license":[{"start":{"date-parts":[[2016,6,8]],"date-time":"2016-06-08T00:00:00Z","timestamp":1465344000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["IJMS"],"abstract":"<jats:p>Parkinsonism is a progressive motor disease that affects 1.5 million Americans and is the second most common neurodegenerative disease after Alzheimer\u2019s. Typical neuropathological features of Parkinson\u2019s disease (PD) include degeneration of dopaminergic neurons located in the pars compacta of the substantia nigra that project to the striatum (nigro-striatal pathway) and depositions of cytoplasmic fibrillary inclusions (Lewy bodies) which contain ubiquitin and \u03b1-synuclein. The cardinal motor signs of PD are tremors, rigidity, slow movement (bradykinesia), poor balance, and difficulty in walking (Parkinsonian gait). In addition to motor symptoms, non-motor symptoms that include autonomic and psychiatric as well as cognitive impairments are pressing issues that need to be addressed. Several different mechanisms play an important role in generation of Lewy bodies; endoplasmic reticulum (ER) stress induced unfolded proteins, neuroinflammation and eventual loss of dopaminergic neurons in the substantia nigra of mid brain in PD. Moreover, these diverse processes that result in PD make modeling of the disease and evaluation of therapeutics against this devastating disease difficult. Here, we will discuss diverse mechanisms that are involved in PD, neuroprotective and therapeutic strategies currently in clinical trial or in preclinical stages, and impart views about strategies that are promising to mitigate PD pathology.<\/jats:p>","DOI":"10.3390\/ijms17060904","type":"journal-article","created":{"date-parts":[[2016,6,8]],"date-time":"2016-06-08T11:26:26Z","timestamp":1465385186000},"page":"904","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":191,"title":["Neuroprotective and Therapeutic Strategies against Parkinson\u2019s Disease: Recent Perspectives"],"prefix":"10.3390","volume":"17","author":[{"given":"Sumit","family":"Sarkar","sequence":"first","affiliation":[{"name":"Division of Neurotoxicology, National Center for Toxicological Research\/FDA, Bldg. 53D, HFT-32, Jefferson, AR 72079, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"James","family":"Raymick","sequence":"additional","affiliation":[{"name":"Division of Neurotoxicology, National Center for Toxicological Research\/FDA, Bldg. 53D, HFT-32, Jefferson, AR 72079, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Syed","family":"Imam","sequence":"additional","affiliation":[{"name":"Division of Neurotoxicology, National Center for Toxicological Research\/FDA, Bldg. 53D, HFT-32, Jefferson, AR 72079, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1968","published-online":{"date-parts":[[2016,6,8]]},"reference":[{"key":"ref_1","unstructured":"Prkinson, J. (1817). An Essay On The Shaking Palsy, Whiitngham and Rowland."},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"1200","DOI":"10.1038\/1801200a0","article-title":"3,4-Dihydroxyphenylalanine and 5-Hydroxytryptophan as Reserpine Antagonists","volume":"180","author":"Carlsson","year":"1957","journal-title":"Nature"},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"293","DOI":"10.1111\/j.1748-1716.1958.tb01628.x","article-title":"A Fluorimetric Method for the Determination of Dopamine (3-Hydroxytyramine)","volume":"44","author":"Carlsson","year":"1958","journal-title":"Acta Physiol. Scand."},{"key":"ref_4","first-page":"183","article-title":"Treatment of Parkinson\u2019s Disease by l-Dopa","volume":"98","author":"Barbeau","year":"1969","journal-title":"Union Med. Can."},{"key":"ref_5","first-page":"787","article-title":"The l-3,4-Dioxyphenylalanine (Dopa)-Effect in Parkinson-Akinesia","volume":"73","author":"Birkmayer","year":"1961","journal-title":"Wien. Klin. Wochenschr."},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"479","DOI":"10.1136\/jnnp.40.5.479","article-title":"Comparison of the Effects of Bromocriptine and Levodopa in Parkinson\u2019s Disease","volume":"40","author":"Smith","year":"1977","journal-title":"J. Neurol. Neurosurg. Psychiatry"},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"337","DOI":"10.1056\/NEJM196902132800701","article-title":"Modification of Parkinsonism\u2014Chronic Treatment with l-Dopa","volume":"280","author":"Cotzias","year":"1969","journal-title":"N. Engl. J. Med."},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"666","DOI":"10.3171\/jns.2002.96.4.0666","article-title":"Bilateral Stimulation of the Subthalamic Nucleus in Patients with Parkinson Disease: A Study of Efficacy and Safety","volume":"96","author":"Simuni","year":"2002","journal-title":"J. Neurosurg."},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"442","DOI":"10.1136\/bmj.4.5942.442","article-title":"Bromocriptine in Parkinsonism","volume":"4","author":"Calne","year":"1974","journal-title":"Br. Med. J."},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"1355","DOI":"10.1016\/S0140-6736(74)92219-3","article-title":"Treatment of Parkinsonism with Bromocriptine","volume":"2","author":"Calne","year":"1974","journal-title":"Lancet"},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"409","DOI":"10.1111\/j.2042-7158.1973.tb10037.x","article-title":"Effect of Ergot Drugs on Central Catecholamine Neurons: Evidence for a Stimulation of Central Dopamine Neurons","volume":"25","author":"Corrodi","year":"1973","journal-title":"J. Pharm. Pharmacol."},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"Iv37","DOI":"10.1007\/s00415-005-4008-5","article-title":"Does Levodopa Slow or Hasten the Rate of Progression of Parkinson\u2019s Disease?","volume":"252","author":"Fahn","year":"2005","journal-title":"J. Neurol."},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"1484","DOI":"10.1056\/NEJM200005183422004","article-title":"A Five-Year Study of the Incidence of Dyskinesia in Patients with Early Parkinson\u2019s Disease Who Were Treated with Ropinirole or Levodopa","volume":"342","author":"Rascol","year":"2000","journal-title":"N. Engl. J. Med."},{"key":"ref_14","first-page":"267","article-title":"Dopaminergic Drugs in Development for Parkinson\u2019s Disease","volume":"91","author":"Korczyn","year":"2003","journal-title":"Adv. Neurol."},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"366","DOI":"10.1016\/0166-2236(89)90074-X","article-title":"The Functional Anatomy of Basal Ganglia Disorders","volume":"12","author":"Albin","year":"1989","journal-title":"Trends Neurosci."},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"141","DOI":"10.1016\/0300-9629(89)90201-6","article-title":"Neural Mechanisms in Disorders of Movement","volume":"93","author":"Crossman","year":"1989","journal-title":"Comp. Biochem. Physiol. Comp. Physiol."},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"281","DOI":"10.1016\/0166-2236(90)90110-V","article-title":"Primate Models of Movement Disorders of Basal Ganglia Origin","volume":"13","author":"Delong","year":"1990","journal-title":"Trends Neurosci."},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"109","DOI":"10.1016\/j.brainresbull.2008.08.020","article-title":"Targeting the Caudal Intralaminar Nuclei for Functional Neurosurgery of Movement Disorders","volume":"78","author":"Benabid","year":"2009","journal-title":"Brain Res. Bull."},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"67","DOI":"10.1016\/S1474-4422(08)70291-6","article-title":"Deep Brain Stimulation of the Subthalamic Nucleus for the Treatment of Parkinson\u2019s Disease","volume":"8","author":"Benabid","year":"2009","journal-title":"Lancet Neurol."},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"265","DOI":"10.1016\/S0079-6123(10)84014-2","article-title":"Neural Grafting in Parkinson\u2019s Disease Problems and Possibilities","volume":"184","author":"Brundin","year":"2010","journal-title":"Prog. Brain Res."},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"710","DOI":"10.1056\/NEJM200103083441002","article-title":"Transplantation of Embryonic Dopamine Neurons for Severe Parkinson\u2019s Disease","volume":"344","author":"Freed","year":"2001","journal-title":"N. Engl. J. Med."},{"key":"ref_22","doi-asserted-by":"crossref","first-page":"403","DOI":"10.1002\/ana.10720","article-title":"A Double-Blind Controlled Trial of Bilateral Fetal Nigral Transplantation in Parkinson\u2019s Disease","volume":"54","author":"Olanow","year":"2003","journal-title":"Ann. Neurol."},{"key":"ref_23","doi-asserted-by":"crossref","first-page":"146","DOI":"10.1016\/j.tins.2007.12.001","article-title":"Critical Issues of Clinical Human Embryonic Stem Cell Therapy for Brain Repair","volume":"31","author":"Li","year":"2008","journal-title":"Trends Neurosci."},{"key":"ref_24","doi-asserted-by":"crossref","first-page":"235","DOI":"10.1016\/S1474-4422(06)70373-8","article-title":"Non-Motor Symptoms of Parkinson\u2019s Disease: Diagnosis and Management","volume":"5","author":"Chaudhuri","year":"2006","journal-title":"Lancet Neurol."},{"key":"ref_25","doi-asserted-by":"crossref","first-page":"717","DOI":"10.1016\/j.parkreldis.2011.02.018","article-title":"Parkinson\u2019s Disease: The Non-Motor Issues","volume":"17","author":"Chaudhuri","year":"2011","journal-title":"Parkinsonism Relat. Disord."},{"key":"ref_26","doi-asserted-by":"crossref","first-page":"464","DOI":"10.1016\/S1474-4422(09)70068-7","article-title":"Non-Motor Symptoms of Parkinson\u2019s Disease: Dopaminergic Pathophysiology and Treatment","volume":"8","author":"Chaudhuri","year":"2009","journal-title":"Lancet Neurol."},{"key":"ref_27","doi-asserted-by":"crossref","first-page":"670","DOI":"10.1001\/archneurol.67.6.670","article-title":"Nonmotor Symptoms in Genetic Parkinson Disease","volume":"67","author":"Kasten","year":"2010","journal-title":"Arch. Neurol."},{"key":"ref_28","doi-asserted-by":"crossref","first-page":"S123","DOI":"10.1002\/mds.22786","article-title":"The Nonmotor Symptoms of Parkinson\u2019s Disease\u2014An Overview","volume":"25","author":"Lim","year":"2010","journal-title":"Mov. Disord."},{"key":"ref_29","doi-asserted-by":"crossref","first-page":"417","DOI":"10.1038\/nrneurol.2010.87","article-title":"Parkinson Disease: Treatment of the Nonmotor Symptoms of Parkinson Disease","volume":"6","author":"Poewe","year":"2010","journal-title":"Nat. Rev. Neurol."},{"key":"ref_30","doi-asserted-by":"crossref","first-page":"295","DOI":"10.2165\/11318330-000000000-00000","article-title":"Clinical Review and Treatment of Select Adverse Effects of Dopamine Receptor Agonists in Parkinson\u2019s Disease","volume":"27","author":"Wood","year":"2010","journal-title":"Drugs Aging"},{"key":"ref_31","doi-asserted-by":"crossref","first-page":"583","DOI":"10.1016\/j.ncl.2009.04.004","article-title":"Etiology and Pathogenesis of Parkinson Disease","volume":"27","author":"Schapira","year":"2009","journal-title":"Neurol. Clin."},{"key":"ref_32","doi-asserted-by":"crossref","first-page":"S44","DOI":"10.1212\/WNL.0b013e3181990438","article-title":"Molecular and Clinical Pathways to Neuroprotection of Dopaminergic Drugs in Parkinson Disease","volume":"72","author":"Schapira","year":"2009","journal-title":"Neurology"},{"key":"ref_33","doi-asserted-by":"crossref","first-page":"295","DOI":"10.1007\/s11910-006-0021-z","article-title":"Preclinical Diagnosis of Parkinson\u2019s Disease: Are We There Yet?","volume":"6","author":"Siderowf","year":"2006","journal-title":"Curr. Neurol. Neurosci. Rep."},{"key":"ref_34","doi-asserted-by":"crossref","first-page":"358","DOI":"10.1001\/jama.291.3.358","article-title":"Neuroprotection in Parkinson Disease: Mysteries, Myths, and Misconceptions","volume":"291","author":"Schapira","year":"2004","journal-title":"JAMA"},{"key":"ref_35","doi-asserted-by":"crossref","first-page":"S665","DOI":"10.1002\/mds.22403","article-title":"Premotor Parkinson\u2019s Disease: Clinical Features and Detection Strategies","volume":"24","author":"Stephenson","year":"2009","journal-title":"Mov. Disord."},{"key":"ref_36","doi-asserted-by":"crossref","first-page":"S1","DOI":"10.1007\/s10654-011-9581-6","article-title":"Epidemiology and Etiology of Parkinson\u2019s Disease: A Review of the Evidence","volume":"26","author":"Wirdefeldt","year":"2011","journal-title":"Eur. J. Epidemiol."},{"key":"ref_37","doi-asserted-by":"crossref","first-page":"334","DOI":"10.1097\/00005072-199804000-00005","article-title":"Nigral and Cortical Lewy Bodies and Dystrophic Nigral Neurites in Parkinson\u2019s Disease and Cortical Lewy Body Disease Contain Alpha-Synuclein Immunoreactivity","volume":"57","author":"Irizarry","year":"1998","journal-title":"J. Neuropathol. Exp. Neurol."},{"key":"ref_38","doi-asserted-by":"crossref","first-page":"6469","DOI":"10.1073\/pnas.95.11.6469","article-title":"Alpha-Synuclein in Filamentous Inclusions of Lewy Bodies from Parkinson\u2019s Disease and Dementia with Lewy Bodies","volume":"95","author":"Spillantini","year":"1998","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"ref_39","doi-asserted-by":"crossref","first-page":"521","DOI":"10.1002\/1531-8249(200004)47:4<521::AID-ANA18>3.0.CO;2-B","article-title":"Synphilin-1 Is Present in Lewy Bodies in Parkinson\u2019s Disease","volume":"47","author":"Wakabayashi","year":"2000","journal-title":"Ann. Neurol."},{"key":"ref_40","doi-asserted-by":"crossref","first-page":"345","DOI":"10.1007\/BF00687787","article-title":"Lewy Bodies Are Ubiquitinated. A Light and Electron Microscopic Immunocytochemical Study","volume":"75","author":"Kuzuhara","year":"1988","journal-title":"Acta Neuropathol."},{"key":"ref_41","doi-asserted-by":"crossref","first-page":"197","DOI":"10.1016\/S0197-4580(02)00065-9","article-title":"Staging of Brain Pathology Related to Sporadic Parkinson\u2019s Disease","volume":"24","author":"Braak","year":"2003","journal-title":"Neurobiol. Aging"},{"key":"ref_42","doi-asserted-by":"crossref","first-page":"1108","DOI":"10.1016\/S1474-4422(11)70227-7","article-title":"Modelling of Parkinson\u2019s Disease in Mice","volume":"10","author":"Chesselet","year":"2011","journal-title":"Lancet Neurol."},{"key":"ref_43","doi-asserted-by":"crossref","first-page":"1022","DOI":"10.1038\/nn.3743","article-title":"Direct and Indirect Pathways of Basal Ganglia: A Critical Reappraisal","volume":"17","author":"Calabresi","year":"2014","journal-title":"Nat. Neurosci."},{"key":"ref_44","doi-asserted-by":"crossref","first-page":"167","DOI":"10.1152\/physiol.00004.2012","article-title":"Striatal Mechanisms Underlying Movement, Reinforcement, and Punishment","volume":"27","author":"Kravitz","year":"2012","journal-title":"Physiology"},{"key":"ref_45","first-page":"S49","article-title":"Parkinson\u2019s Disease\u2014Part 2: Treatment of Motor Symptoms","volume":"14","author":"Weintraub","year":"2008","journal-title":"Am. J. Manag. Care"},{"key":"ref_46","first-page":"S59","article-title":"Parkinson\u2019s Disease\u2014Part 3: Neuropsychiatric Symptoms","volume":"14","author":"Weintraub","year":"2008","journal-title":"Am. J. Manag. Care"},{"key":"ref_47","doi-asserted-by":"crossref","first-page":"1478","DOI":"10.1002\/mds.25135","article-title":"Living on the Edge with Too Many Mouths to Feed: Why Dopamine Neurons Die","volume":"27","author":"Bolam","year":"2012","journal-title":"Mov. Disord."},{"key":"ref_48","doi-asserted-by":"crossref","first-page":"513","DOI":"10.1016\/j.tins.2010.08.002","article-title":"Early Synaptic Pathophysiology in Neurodegeneration: Insights from Huntington\u2019s Disease","volume":"33","author":"Milnerwood","year":"2010","journal-title":"Trends Neurosci."},{"key":"ref_49","doi-asserted-by":"crossref","first-page":"72","DOI":"10.1016\/j.expneurol.2012.01.011","article-title":"Axon Degeneration in Parkinson\u2019s Disease","volume":"246","author":"Burke","year":"2013","journal-title":"Exp. Neurol."},{"key":"ref_50","doi-asserted-by":"crossref","first-page":"676","DOI":"10.1016\/j.bbadis.2008.09.009","article-title":"Targets for Neuroprotection in Parkinson\u2019s Disease","volume":"1792","author":"Yacoubian","year":"2009","journal-title":"Biochim. Biophys. Acta"},{"key":"ref_51","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.brainres.2006.11.032","article-title":"Pyruvate Protects Mitochondria from Oxidative Stress in Human Neuroblastoma Sk-N-Sh Cells","volume":"1132","author":"Wang","year":"2007","journal-title":"Brain Res."},{"key":"ref_52","doi-asserted-by":"crossref","first-page":"44","DOI":"10.1016\/j.biocel.2006.07.001","article-title":"Free Radicals and Antioxidants in Normal Physiological Functions and Human Disease","volume":"39","author":"Valko","year":"2007","journal-title":"Int. J. Biochem. Cell Biol."},{"key":"ref_53","doi-asserted-by":"crossref","first-page":"1196","DOI":"10.1046\/j.1471-4159.1997.69031196.x","article-title":"Oxidative Dna Damage in the Parkinsonian Brain: An Apparent Selective Increase in 8-Hydroxyguanine Levels in Substantia Nigra","volume":"69","author":"Alam","year":"1997","journal-title":"J. Neurochem."},{"key":"ref_54","doi-asserted-by":"crossref","first-page":"38","DOI":"10.1002\/ana.410350107","article-title":"Indices of Oxidative Stress and Mitochondrial Function in Individuals with Incidental Lewy Body Disease","volume":"35","author":"Dexter","year":"1994","journal-title":"Ann. Neurol."},{"key":"ref_55","doi-asserted-by":"crossref","first-page":"1269","DOI":"10.1016\/S0140-6736(89)92366-0","article-title":"Mitochondrial Complex I Deficiency in Parkinson\u2019s Disease","volume":"1","author":"Schapira","year":"1989","journal-title":"Lancet"},{"key":"ref_56","doi-asserted-by":"crossref","first-page":"1301","DOI":"10.1038\/81834","article-title":"Chronic Systemic Pesticide Exposure Reproduces Features of Parkinson\u2019s Disease","volume":"3","author":"Betarbet","year":"2000","journal-title":"Nat. Neurosci."},{"key":"ref_57","doi-asserted-by":"crossref","first-page":"979","DOI":"10.1126\/science.6823561","article-title":"Chronic Parkinsonism in Humans Due to a Product of Meperidine-Analog Synthesis","volume":"219","author":"Langston","year":"1983","journal-title":"Science"},{"key":"ref_58","doi-asserted-by":"crossref","first-page":"390","DOI":"10.1016\/0006-8993(84)90777-7","article-title":"Selective Nigral Toxicity after Systemic Administration of 1-Methyl-4-Phenyl-1,2,5,6-Tetrahydropyrine (Mptp) in the Squirrel Monkey","volume":"292","author":"Langston","year":"1984","journal-title":"Brain Res."},{"key":"ref_59","doi-asserted-by":"crossref","first-page":"1343","DOI":"10.1016\/j.neurobiolaging.2004.11.008","article-title":"Somatic Mitochondrial Dna Mutations in Single Neurons and Glia","volume":"26","author":"Lin","year":"2005","journal-title":"Neurobiol. Aging"},{"key":"ref_60","doi-asserted-by":"crossref","first-page":"97","DOI":"10.1016\/S1474-4422(07)70327-7","article-title":"Mitochondria in the Aetiology and Pathogenesis of Parkinson\u2019s Disease","volume":"7","author":"Schapira","year":"2008","journal-title":"Lancet Neurol."},{"key":"ref_61","doi-asserted-by":"crossref","first-page":"265","DOI":"10.1002\/ana.410410218","article-title":"Maternal Inheritance in Parkinson\u2019s Disease","volume":"41","author":"Wooten","year":"1997","journal-title":"Ann. Neurol."},{"key":"ref_62","doi-asserted-by":"crossref","first-page":"515","DOI":"10.1111\/j.1471-4159.1989.tb09150.x","article-title":"Transition Metals, Ferritin, Glutathione, and Ascorbic Acid in Parkinsonian Brains","volume":"52","author":"Riederer","year":"1989","journal-title":"J. Neurochem."},{"key":"ref_63","doi-asserted-by":"crossref","first-page":"269","DOI":"10.1016\/0304-3940(86)90320-4","article-title":"Idiopathic Parkinson\u2019s Disease, Progressive Supranuclear Palsy and Glutathione Metabolism in the Substantia Nigra of Patients","volume":"67","author":"Perry","year":"1986","journal-title":"Neurosci. Lett."},{"key":"ref_64","doi-asserted-by":"crossref","first-page":"348","DOI":"10.1002\/ana.410360305","article-title":"Alterations in Glutathione Levels in Parkinson\u2019s Disease and Other Neurodegenerative Disorders Affecting Basal Ganglia","volume":"36","author":"Sian","year":"1994","journal-title":"Ann. Neurol."},{"key":"ref_65","doi-asserted-by":"crossref","first-page":"128","DOI":"10.1016\/0304-3940(92)90355-B","article-title":"Reduced and Oxidized Glutathione in the Substantia Nigra of Patients with Parkinson\u2019s Disease","volume":"142","author":"Sofic","year":"1992","journal-title":"Neurosci. Lett."},{"key":"ref_66","doi-asserted-by":"crossref","first-page":"1162","DOI":"10.1038\/nature04779","article-title":"Drosophila Pink1 Is Required for Mitochondrial Function and Interacts Genetically with Parkin","volume":"441","author":"Clark","year":"2006","journal-title":"Nature"},{"key":"ref_67","doi-asserted-by":"crossref","first-page":"5215","DOI":"10.1073\/pnas.0501282102","article-title":"Hypersensitivity of Dj-1-Deficient Mice to 1-Methyl-4-Phenyl-1,2,3,6-Tetrahydropyrindine (Mptp) and Oxidative Stress","volume":"102","author":"Kim","year":"2005","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"ref_68","doi-asserted-by":"crossref","first-page":"1157","DOI":"10.1038\/nature04788","article-title":"Mitochondrial Dysfunction in Drosophila Pink1 Mutants Is Complemented by Parkin","volume":"441","author":"Park","year":"2006","journal-title":"Nature"},{"key":"ref_69","doi-asserted-by":"crossref","first-page":"S41","DOI":"10.1016\/S1353-8020(09)70834-X","article-title":"Neuroprotection in Parkinson\u2019s Disease","volume":"15","author":"Schapira","year":"2009","journal-title":"Parkinsonism Relat. Disord."},{"key":"ref_70","doi-asserted-by":"crossref","first-page":"707","DOI":"10.1016\/j.bbrc.2007.01.043","article-title":"Activation of the Unfolded Protein Response in Parkinson\u2019s Disease","volume":"354","author":"Hoozemans","year":"2007","journal-title":"Biochem. Biophys. Res. Commun."},{"key":"ref_71","doi-asserted-by":"crossref","first-page":"605","DOI":"10.1038\/33416","article-title":"Mutations in the Parkin Gene Cause Autosomal Recessive Juvenile Parkinsonism","volume":"392","author":"Kitada","year":"1998","journal-title":"Nature"},{"key":"ref_72","doi-asserted-by":"crossref","first-page":"891","DOI":"10.1016\/S0092-8674(01)00407-X","article-title":"An Unfolded Putative Transmembrane Polypeptide, Which Can Lead to Endoplasmic Reticulum Stress, Is a Substrate of Parkin","volume":"105","author":"Imai","year":"2001","journal-title":"Cell"},{"key":"ref_73","doi-asserted-by":"crossref","first-page":"250","DOI":"10.1016\/j.neuro.2014.07.006","article-title":"Neuroprotective Effect of the Chemical Chaperone, Trehalose in a Chronic Mptp-Induced Parkinson\u2019s Disease Mouse Model","volume":"44","author":"Sarkar","year":"2014","journal-title":"Neurotoxicology"},{"key":"ref_74","doi-asserted-by":"crossref","first-page":"451","DOI":"10.1038\/26652","article-title":"The Ubiquitin Pathway in Parkinson\u2019s Disease","volume":"395","author":"Leroy","year":"1998","journal-title":"Nature"},{"key":"ref_75","doi-asserted-by":"crossref","first-page":"25497","DOI":"10.1074\/jbc.M400255200","article-title":"Hsp70 Reduces Alpha-Synuclein Aggregation and Toxicity","volume":"279","author":"Klucken","year":"2004","journal-title":"J. Biol. Chem."},{"key":"ref_76","doi-asserted-by":"crossref","first-page":"1806","DOI":"10.1111\/j.1471-4159.2008.05261.x","article-title":"Parkin Mediates the Degradation-Independent Ubiquitination of Hsp70","volume":"105","author":"Moore","year":"2008","journal-title":"J. Neurochem."},{"key":"ref_77","doi-asserted-by":"crossref","first-page":"S7","DOI":"10.1016\/S0166-2236(00)01998-6","article-title":"The Role of the Ubiquitin-Proteasomal Pathway in Parkinson\u2019s Disease and Other Neurodegenerative Disorders","volume":"24","author":"Chung","year":"2001","journal-title":"Trends Neurosci."},{"key":"ref_78","doi-asserted-by":"crossref","first-page":"301","DOI":"10.1046\/j.1471-4159.2002.00821.x","article-title":"Impairment of the Ubiquitin-Proteasome System Causes Dopaminergic Cell Death and Inclusion Body Formation in Ventral Mesencephalic Cultures","volume":"81","author":"Mcnaught","year":"2002","journal-title":"J. Neurochem."},{"key":"ref_79","doi-asserted-by":"crossref","first-page":"176","DOI":"10.1016\/S0006-291X(03)00555-2","article-title":"Alterations of Structure and Hydrolase Activity of Parkinsonism-Associated Human Ubiquitin Carboxyl-Terminal Hydrolase L1 Variants","volume":"304","author":"Nishikawa","year":"2003","journal-title":"Biochem. Biophys. Res. Commun."},{"key":"ref_80","doi-asserted-by":"crossref","first-page":"295","DOI":"10.1016\/j.expneurol.2007.02.008","article-title":"Non-Steroidal Anti-Inflammatory Drugs in Parkinson\u2019s Disease","volume":"205","author":"Esposito","year":"2007","journal-title":"Exp. Neurol."},{"key":"ref_81","doi-asserted-by":"crossref","first-page":"789","DOI":"10.2165\/00023210-200721100-00001","article-title":"The Role of Anti-Inflammatory Agents in Parkinson\u2019s Disease","volume":"21","author":"Mcgeer","year":"2007","journal-title":"CNS Drugs"},{"key":"ref_82","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.expneurol.2007.07.004","article-title":"Neuroinflammatory Mechanisms in Parkinson\u2019s Disease: Potential Environmental Triggers, Pathways, and Targets for Early Therapeutic Intervention","volume":"208","author":"Tansey","year":"2007","journal-title":"Exp. Neurol."},{"key":"ref_83","doi-asserted-by":"crossref","first-page":"1095","DOI":"10.2337\/db06-0322","article-title":"Effects of Diazoxide on Gene Expression in Rat Pancreatic Islets Are Largely Linked to Elevated Glucose and Potentially Serve to Enhance Beta-Cell Sensitivity","volume":"56","author":"Ma","year":"2007","journal-title":"Diabetes"},{"key":"ref_84","doi-asserted-by":"crossref","first-page":"147","DOI":"10.1016\/0304-3940(94)90508-8","article-title":"Interleukin-1 Beta, Interleukin-6, Epidermal Growth Factor and Transforming Growth Factor-Alpha Are Elevated in the Brain from Parkinsonian Patients","volume":"180","author":"Mogi","year":"1994","journal-title":"Neurosci. Lett."},{"key":"ref_85","doi-asserted-by":"crossref","first-page":"208","DOI":"10.1016\/0304-3940(94)90746-3","article-title":"Tumor Necrosis Factor-Alpha (Tnf-Alpha) Increases Both in the Brain and in the Cerebrospinal Fluid from Parkinsonian Patients","volume":"165","author":"Mogi","year":"1994","journal-title":"Neurosci. Lett."},{"key":"ref_86","doi-asserted-by":"crossref","first-page":"321","DOI":"10.1016\/j.bbrc.2009.08.150","article-title":"Abnormal Serum Concentrations of Proteins in Parkinson\u2019s Disease","volume":"389","author":"Goldknopf","year":"2009","journal-title":"Biochem. Biophys. Res. Commun."},{"key":"ref_87","doi-asserted-by":"crossref","first-page":"100","DOI":"10.1007\/BF00427222","article-title":"Lewy Bodies in Parkinson\u2019s Disease Are Recognized by Antibodies to Complement Proteins","volume":"84","author":"Yamada","year":"1992","journal-title":"Acta Neuropathol."},{"key":"ref_88","doi-asserted-by":"crossref","first-page":"1083","DOI":"10.1189\/jlb.0507296","article-title":"Neuroprotective Activities of Cd4+Cd25+ Regulatory T Cells in an Animal Model of Parkinson\u2019s Disease","volume":"82","author":"Reynolds","year":"2007","journal-title":"J. Leukoc. Biol."},{"key":"ref_89","doi-asserted-by":"crossref","first-page":"1504","DOI":"10.1111\/j.1471-4159.2007.05087.x","article-title":"Nitrated Alpha-Synuclein-Activated Microglial Profiling for Parkinson\u2019s Disease","volume":"104","author":"Reynolds","year":"2008","journal-title":"J. Neurochem."},{"key":"ref_90","doi-asserted-by":"crossref","first-page":"59","DOI":"10.1007\/s11481-008-9100-z","article-title":"Nitrated Alpha-Synuclein and Microglial Neuroregulatory Activities","volume":"3","author":"Reynolds","year":"2008","journal-title":"J. Neuroimmune Pharmacol."},{"key":"ref_91","doi-asserted-by":"crossref","first-page":"533","DOI":"10.1096\/fj.04-2751com","article-title":"Aggregated Alpha-Synuclein Activates Microglia: A Process Leading to Disease Progression in Parkinson\u2019s Disease","volume":"19","author":"Zhang","year":"2005","journal-title":"FASEB J."},{"key":"ref_92","doi-asserted-by":"crossref","unstructured":"Benner, E.J., Banerjee, R., Reynolds, A.D., Sherman, S., Pisarev, V.M., Tsiperson, V., Nemachek, C., Ciborowski, P., Przedborski, S., and Mosley, R.L. (2008). Nitrated Alpha-Synuclein Immunity Accelerates Degeneration of Nigral Dopaminergic Neurons. PLoS ONE, 3.","DOI":"10.1371\/journal.pone.0001376"},{"key":"ref_93","doi-asserted-by":"crossref","first-page":"1149","DOI":"10.1097\/NEN.0b013e31818e5e99","article-title":"Targeted Overexpression of Human Alpha-Synuclein Triggers Microglial Activation and an Adaptive Immune Response in a Mouse Model of Parkinson Disease","volume":"67","author":"Theodore","year":"2008","journal-title":"J. Neuropathol. Exp. Neurol."},{"key":"ref_94","doi-asserted-by":"crossref","first-page":"18754","DOI":"10.1073\/pnas.0704908104","article-title":"Selective Inhibition of Nf-Kappab Activation Prevents Dopaminergic Neuronal Loss in a Mouse Model of Parkinson\u2019s Disease","volume":"104","author":"Ghosh","year":"2007","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"ref_95","doi-asserted-by":"crossref","first-page":"494","DOI":"10.1212\/01.wnl.0000227906.99570.cc","article-title":"Immunologic Diseases, Anti-Inflammatory Drugs, and Parkinson Disease: A Case-Control Study","volume":"67","author":"Bower","year":"2006","journal-title":"Neurology"},{"key":"ref_96","doi-asserted-by":"crossref","first-page":"1059","DOI":"10.1001\/archneur.60.8.1059","article-title":"Nonsteroidal Anti-Inflammatory Drugs and the Risk of Parkinson Disease","volume":"60","author":"Chen","year":"2003","journal-title":"Arch. Neurol."},{"key":"ref_97","doi-asserted-by":"crossref","first-page":"1097","DOI":"10.1212\/01.wnl.0000204446.82823.28","article-title":"Nonsteroidal Anti-Inflammatory Drugs and the Incidence of Parkinson Disease","volume":"66","author":"Hernan","year":"2006","journal-title":"Neurology"},{"key":"ref_98","doi-asserted-by":"crossref","unstructured":"Wolozin, B., Wang, S.W., Li, N.C., Lee, A., Lee, T.A., and Kazis, L.E. (2007). Simvastatin Is Associated with a Reduced Incidence of Dementia and Parkinson\u2019s Disease. BMC Med., 5.","DOI":"10.1186\/1741-7015-5-20"},{"key":"ref_99","doi-asserted-by":"crossref","unstructured":"The NINDS NET-PD Investigators (2006). A Randomized, Double-Blind, Futility Clinical Trial of Creatine and Minocycline in Early Parkinson Disease. Neurology, 66, 664\u2013671.","DOI":"10.1212\/01.wnl.0000201252.57661.e1"},{"key":"ref_100","doi-asserted-by":"crossref","first-page":"356","DOI":"10.1016\/S0165-6147(00)89070-7","article-title":"Nmda Receptor-Dependent Excitotoxicity: The Role of Intracellular Ca2+ Release","volume":"16","author":"Mody","year":"1995","journal-title":"Trends Pharmacol. Sci."},{"key":"ref_101","doi-asserted-by":"crossref","first-page":"179","DOI":"10.1016\/0891-0618(96)00148-2","article-title":"Nitric Oxide Neurotoxicity","volume":"10","author":"Dawson","year":"1996","journal-title":"J. Chem. Neuroanat."},{"key":"ref_102","doi-asserted-by":"crossref","first-page":"338","DOI":"10.1097\/00005072-199804000-00006","article-title":"Protein Nitration in Parkinson\u2019s Disease","volume":"57","author":"Good","year":"1998","journal-title":"J. Neuropathol. Exp. Neurol."},{"key":"ref_103","doi-asserted-by":"crossref","first-page":"387","DOI":"10.1097\/00001756-199304000-00011","article-title":"Nmda Antagonists Partially Protect Against Mptp Induced Neurotoxicity in Mice","volume":"4","author":"Brouillet","year":"1993","journal-title":"Neuroreport"},{"key":"ref_104","doi-asserted-by":"crossref","first-page":"414","DOI":"10.1038\/349414a0","article-title":"Protection of Substantia Nigra from Mpp+ Neurotoxicity by N-Methyl-d-Aspartate Antagonists","volume":"349","author":"Turski","year":"1991","journal-title":"Nature"},{"key":"ref_105","doi-asserted-by":"crossref","first-page":"271","DOI":"10.1016\/S1353-8020(01)00040-2","article-title":"A Double-Blind, Placebo-Controlled and Longitudinal Study of Riluzole in Early Parkinson\u2019s Disease","volume":"8","author":"Jankovic","year":"2002","journal-title":"Parkinsonism Relat. Disord."},{"key":"ref_106","first-page":"91","article-title":"Amantadine and Memantine Are Nmda Receptor Antagonists with Neuroprotective Properties","volume":"43","author":"Kornhuber","year":"1994","journal-title":"J. Neural. Transm. Suppl."},{"key":"ref_107","doi-asserted-by":"crossref","first-page":"155","DOI":"10.1016\/j.pharmthera.2004.04.001","article-title":"Rationale for and Use of Nmda Receptor Antagonists in Parkinson\u2019s Disease","volume":"102","author":"Hallett","year":"2004","journal-title":"Pharmacol. Ther."},{"key":"ref_108","first-page":"25","article-title":"Apoptosis and Autophagy in Nigral Neurons of Patients with Parkinson\u2019s Disease","volume":"12","author":"Anglade","year":"1997","journal-title":"Histol. Histopathol."},{"key":"ref_109","first-page":"9","article-title":"Glial Cell Participation in the Degeneration of Dopaminergic Neurons in Parkinson\u2019s Disease","volume":"80","author":"Hirsch","year":"1999","journal-title":"Adv. Neurol."},{"key":"ref_110","first-page":"119","article-title":"Apoptotic-Like Changes in Lewy-Body-Associated Disorders and Normal Aging in Substantia Nigral Neurons","volume":"150","author":"Tompkins","year":"1997","journal-title":"Am. J. Pathol."},{"key":"ref_111","doi-asserted-by":"crossref","first-page":"135","DOI":"10.1016\/S0301-0082(01)00003-X","article-title":"Molecular Pathways Involved in the Neurotoxicity of 6-Ohda, Dopamine and Mptp: Contribution to the Apoptotic Theory in Parkinson\u2019s Disease","volume":"65","author":"Blum","year":"2001","journal-title":"Prog. Neurobiol."},{"key":"ref_112","doi-asserted-by":"crossref","first-page":"1997","DOI":"10.1089\/ars.2006.8.1997","article-title":"Neuronal Life-and-Death Signaling, Apoptosis, and Neurodegenerative Disorders","volume":"8","author":"Mattson","year":"2006","journal-title":"Antioxid. Redox Signal."},{"key":"ref_113","doi-asserted-by":"crossref","unstructured":"Parkinson Study Group PRECEPT Investigators (2007). Mixed Lineage Kinase Inhibitor Cep-1347 Fails to Delay Disability in Early Parkinson Disease. Neurology, 69, 1480\u20131490.","DOI":"10.1212\/01.wnl.0000277648.63931.c0"},{"key":"ref_114","doi-asserted-by":"crossref","first-page":"45","DOI":"10.1016\/S0304-3940(99)00463-2","article-title":"Brain-Derived Growth Factor and Nerve Growth Factor Concentrations Are Decreased in the Substantia Nigra in Parkinson\u2019s Disease","volume":"270","author":"Mogi","year":"1999","journal-title":"Neurosci. Lett."},{"key":"ref_115","doi-asserted-by":"crossref","first-page":"277","DOI":"10.1016\/S0891-0618(01)00115-6","article-title":"Depletion of Glial Cell Line-Derived Neurotrophic Factor in Substantia Nigra Neurons of Parkinson\u2019s Disease Brain","volume":"21","author":"Chauhan","year":"2001","journal-title":"J. Chem. Neuroanat."},{"key":"ref_116","doi-asserted-by":"crossref","first-page":"769","DOI":"10.1523\/JNEUROSCI.4421-04.2005","article-title":"Continuous Low-Level Glial Cell Line-Derived Neurotrophic Factor Delivery Using Recombinant Adeno-Associated Viral Vectors Provides Neuroprotection and Induces Behavioral Recovery in a Primate Model of Parkinson\u2019s Disease","volume":"25","author":"Eslamboli","year":"2005","journal-title":"J. Neurosci."},{"key":"ref_117","doi-asserted-by":"crossref","first-page":"62","DOI":"10.1038\/sj.mt.6300010","article-title":"Striatal Delivery of Neurturin by Cere-120, an AAV2 Vector for the Treatment of Dopaminergic Neuron Degeneration in Parkinson\u2019s Disease","volume":"15","author":"Gasmi","year":"2007","journal-title":"Mol. Ther."},{"key":"ref_118","doi-asserted-by":"crossref","first-page":"2303","DOI":"10.1002\/mds.22369","article-title":"Transplanted Dopaminergic Neurons Develop PD Pathologic Changes: A Second Case Report","volume":"23","author":"Kordower","year":"2008","journal-title":"Mov. Disord."},{"key":"ref_119","doi-asserted-by":"crossref","first-page":"589","DOI":"10.1038\/nm850","article-title":"Direct Brain Infusion of Glial Cell Line-Derived Neurotrophic Factor in Parkinson Disease","volume":"9","author":"Gill","year":"2003","journal-title":"Nat. Med."},{"key":"ref_120","doi-asserted-by":"crossref","first-page":"459","DOI":"10.1002\/ana.20737","article-title":"Randomized Controlled Trial of Intraputamenal Glial Cell Line-Derived Neurotrophic Factor Infusion in Parkinson Disease","volume":"59","author":"Lang","year":"2006","journal-title":"Ann. Neurol."},{"key":"ref_121","doi-asserted-by":"crossref","first-page":"123","DOI":"10.1146\/annurev.neuro.22.1.123","article-title":"Etiology and Pathogenesis of Parkinson\u2019s Disease","volume":"22","author":"Olanow","year":"1999","journal-title":"Annu. Rev. Neurosci."},{"key":"ref_122","doi-asserted-by":"crossref","first-page":"343","DOI":"10.1001\/archneur.1969.00480160015001","article-title":"Treatment of Parkinsonism with Levodopa","volume":"21","author":"Yahr","year":"1969","journal-title":"Arch. Neurol."},{"key":"ref_123","doi-asserted-by":"crossref","first-page":"985","DOI":"10.1016\/S0140-6736(70)92169-0","article-title":"Levodopa and Adventitious Movements","volume":"2","author":"Lieberman","year":"1970","journal-title":"Lancet"},{"key":"ref_124","doi-asserted-by":"crossref","first-page":"193","DOI":"10.1001\/archneur.1970.00480270003001","article-title":"Psychosis and Other Psychiatric Manifestations of Levodopa Therapy","volume":"23","author":"Celesia","year":"1970","journal-title":"Arch. Neurol."},{"key":"ref_125","doi-asserted-by":"crossref","first-page":"751","DOI":"10.7326\/0003-4819-72-5-751","article-title":"Levodopa, Parkinson\u2019s Disease, and Hypotension","volume":"72","author":"Mcdowell","year":"1970","journal-title":"Ann. Intern. Med."},{"key":"ref_126","doi-asserted-by":"crossref","first-page":"575","DOI":"10.1016\/S0140-6736(02)09733-7","article-title":"Levodopa: Why the Controversy?","volume":"360","author":"Agid","year":"2002","journal-title":"Lancet"},{"key":"ref_127","doi-asserted-by":"crossref","first-page":"2498","DOI":"10.1056\/NEJMoa033447","article-title":"Levodopa and the Progression of Parkinson\u2019s Disease","volume":"351","author":"Fahn","year":"2004","journal-title":"N. Engl. J. Med."},{"key":"ref_128","first-page":"230","article-title":"Dopaminergic Agonists in Parkinson\u2019s Disease","volume":"29","author":"Burguera","year":"2014","journal-title":"Neurologia"},{"key":"ref_129","doi-asserted-by":"crossref","first-page":"330","DOI":"10.1016\/j.amjopharm.2006.12.001","article-title":"Rasagiline (Tvp-1012): A New Selective Monoamine Oxidase Inhibitor for Parkinson\u2019s Disease","volume":"4","author":"Guay","year":"2006","journal-title":"Am. J. Geriatr. Pharmacother."},{"key":"ref_130","doi-asserted-by":"crossref","first-page":"337","DOI":"10.2147\/NDT.S2325","article-title":"Update on the Use of Pramipexole in the Treatment of Parkinson\u2019s Disease","volume":"4","author":"Constantinescu","year":"2008","journal-title":"Neuropsychiatr. Dis. Treat."},{"key":"ref_131","doi-asserted-by":"crossref","first-page":"S387","DOI":"10.1007\/s10072-008-1054-7","article-title":"Continuous Dopaminergic Stimulation Achieved by Duodenal Levodopa Infusion","volume":"29","author":"Odin","year":"2008","journal-title":"Neurol. Sci."},{"key":"ref_132","first-page":"39","article-title":"Anticholinergic Drugs Used in Parkinson\u2019s Disease: An Overlooked Class of Drugs from a Pharmacokinetic Perspective","volume":"2","author":"Brocks","year":"1999","journal-title":"J. Pharm. Pharm. Sci."},{"key":"ref_133","doi-asserted-by":"crossref","first-page":"1472","DOI":"10.1136\/jnnp.2004.035980","article-title":"Present and Future Drug Treatment for Parkinson\u2019s Disease","volume":"76","author":"Schapira","year":"2005","journal-title":"J. Neurol. Neurosurg. Psychiatry"},{"key":"ref_134","doi-asserted-by":"crossref","first-page":"1263","DOI":"10.1212\/WNL.0b013e3181f6128c","article-title":"Effects of a Central Cholinesterase Inhibitor on Reducing Falls in Parkinson Disease","volume":"75","author":"Chung","year":"2010","journal-title":"Neurology"},{"key":"ref_135","doi-asserted-by":"crossref","unstructured":"Henderson, E.J., Lord, S.R., Close, J.C., Lawrence, A.D., Whone, A., and Ben-Shlomo, Y. (2013). The Respond Trial\u2014Rivastigmine to Stabilise Gait in Parkinson\u2019s Disease a Phase II, Randomised, Double Blind, Placebo Controlled Trial to Evaluate the Effect of Rivastigmine on Gait in Patients with Parkinson\u2019s Disease Who Have Fallen. BMC Neurol., 13.","DOI":"10.1186\/1471-2377-13-188"},{"key":"ref_136","doi-asserted-by":"crossref","first-page":"209","DOI":"10.1007\/BF01273182","article-title":"Attenuation of Levodopa-Induced Toxicity in Mesencephalic Cultures by Pramipexole","volume":"104","author":"Carvey","year":"1997","journal-title":"J. Neural. Transm."},{"key":"ref_137","doi-asserted-by":"crossref","first-page":"295","DOI":"10.1046\/j.1471-4159.1998.71010295.x","article-title":"Pramipexole Reduces Reactive Oxygen Species Production in Vivo and in Vitro and Inhibits the Mitochondrial Permeability Transition Produced by the Parkinsonian Neurotoxin Methylpyridinium Ion","volume":"71","author":"Cassarino","year":"1998","journal-title":"J. Neurochem."},{"key":"ref_138","doi-asserted-by":"crossref","first-page":"1315","DOI":"10.1111\/j.1471-4159.2005.03625.x","article-title":"Pramipexole Protects Against Mptp Toxicity in Non-Human Primates","volume":"96","author":"Iravani","year":"2006","journal-title":"J. Neurochem."},{"key":"ref_139","doi-asserted-by":"crossref","first-page":"1046","DOI":"10.1124\/mol.54.6.1046","article-title":"Protective Effects of the Antiparkinsonian Drugs Talipexole and Pramipexole Against 1-Methyl-4-Phenylpyridinium-Induced Apoptotic Death in Human Neuroblastoma Sh-Sy5y Cells","volume":"54","author":"Kitamura","year":"1998","journal-title":"Mol. Pharmacol."},{"key":"ref_140","doi-asserted-by":"crossref","first-page":"207","DOI":"10.1016\/0006-8993(94)90969-5","article-title":"Bromocriptine Protects Mice Against 6-Hydroxydopamine and Scavenges Hydroxyl Free Radicals in Vitro","volume":"657","author":"Ogawa","year":"1994","journal-title":"Brain Res."},{"key":"ref_141","doi-asserted-by":"crossref","unstructured":"Parkinson Study Group (2002). Dopamine Transporter Brain Imaging to Assess the Effects of Pramipexole vs. Levodopa on Parkinson Disease Progression. JAMA, 287, 1653\u20131661.","DOI":"10.1001\/jama.287.13.1653"},{"key":"ref_142","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1016\/j.pneurobio.2007.10.003","article-title":"Disease-Modifying Drugs and Parkinson\u2019s Disease","volume":"84","author":"Allain","year":"2008","journal-title":"Prog. Neurobiol."},{"key":"ref_143","doi-asserted-by":"crossref","first-page":"208","DOI":"10.1212\/01.WNL.0000149403.14458.7F","article-title":"The Role of Radiotracer Imaging in Parkinson Disease","volume":"64","author":"Ravina","year":"2005","journal-title":"Neurology"},{"key":"ref_144","doi-asserted-by":"crossref","unstructured":"The Parkinson Study Group (1989). Effect of Deprenyl on the Progression of Disability in Early Parkinson\u2019s Disease. N. Engl. J. Med., 321, 1364\u20131371.","DOI":"10.1056\/NEJM198911163212004"},{"key":"ref_145","doi-asserted-by":"crossref","unstructured":"Parkinson Study Group (1993). Effects of Tocopherol and Deprenyl on the Progression of Disability in Early Parkinson\u2019s Disease. N. Engl. J. Med., 328, 176\u2013183.","DOI":"10.1056\/NEJM199301213280305"},{"key":"ref_146","doi-asserted-by":"crossref","unstructured":"Parkinson Study Group (2004). A Controlled, Randomized, Delayed-Start Study of Rasagiline in Early Parkinson Disease. Arch. Neurol., 61, 561\u2013566.","DOI":"10.1001\/archneur.61.4.561"},{"key":"ref_147","doi-asserted-by":"crossref","first-page":"109","DOI":"10.1016\/S0006-8993(97)01192-X","article-title":"Coenzyme Q10 Attenuates the 1-Methyl-4-Phenyl-1,2,3,Tetrahydropyridine (Mptp) Induced Loss of Striatal Dopamine and Dopaminergic Axons in Aged Mice","volume":"783","author":"Beal","year":"1998","journal-title":"Brain Res."},{"key":"ref_148","doi-asserted-by":"crossref","first-page":"1541","DOI":"10.1001\/archneur.59.10.1541","article-title":"Effects of Coenzyme Q10 in Early Parkinson Disease: Evidence of Slowing of the Functional Decline","volume":"59","author":"Shults","year":"2002","journal-title":"Arch. Neurol."},{"key":"ref_149","doi-asserted-by":"crossref","first-page":"142","DOI":"10.1006\/exnr.1999.7049","article-title":"Creatine and Cyclocreatine Attenuate Mptp Neurotoxicity","volume":"157","author":"Matthews","year":"1999","journal-title":"Exp. Neurol."},{"key":"ref_150","doi-asserted-by":"crossref","first-page":"1013","DOI":"10.1016\/S1474-4422(06)70602-0","article-title":"Tch346 As a Neuroprotective Drug in Parkinson\u2019s Disease: A Double-Blind, Randomised, Controlled Trial","volume":"5","author":"Olanow","year":"2006","journal-title":"Lancet Neurol."},{"key":"ref_151","doi-asserted-by":"crossref","first-page":"6329","DOI":"10.1523\/JNEUROSCI.1746-05.2005","article-title":"Progressive Degeneration of Human Mesencephalic Neuron-Derived Cells Triggered by Dopamine-Dependent Oxidative Stress Is Dependent on the Mixed-Lineage Kinase Pathway","volume":"25","author":"Lotharius","year":"2005","journal-title":"J. Neurosci."},{"key":"ref_152","doi-asserted-by":"crossref","first-page":"86","DOI":"10.1016\/j.brainres.2003.11.073","article-title":"Inhibition of Mixed Lineage Kinase 3 Attenuates Mpp+-Induced Neurotoxicity in Sh-Sy5y Cells","volume":"1003","author":"Mathiasen","year":"2004","journal-title":"Brain Res."},{"key":"ref_153","first-page":"421","article-title":"Cep-1347\/Kt-7515, an Inhibitor of C-Jun N-Terminal Kinase Activation, Attenuates the 1-Methyl-4-Phenyl Tetrahydropyridine-Mediated Loss of Nigrostriatal Dopaminergic Neurons in Vivo","volume":"288","author":"Saporito","year":"1999","journal-title":"J. Pharmacol. Exp. Ther."},{"key":"ref_154","doi-asserted-by":"crossref","first-page":"767","DOI":"10.1126\/science.290.5492.767","article-title":"Neurodegeneration Prevented by Lentiviral Vector Delivery of Gdnf in Primate Models of Parkinson\u2019s Disease","volume":"290","author":"Kordower","year":"2000","journal-title":"Science"},{"key":"ref_155","doi-asserted-by":"crossref","first-page":"70","DOI":"10.1046\/j.1471-4159.1999.0730070.x","article-title":"Differential Effects of Glial Cell Line-Derived Neurotrophic Factor and Neurturin on Developing and Adult Substantia Nigra Dopaminergic Neurons","volume":"73","author":"Akerud","year":"1999","journal-title":"J. Neurochem."},{"key":"ref_156","doi-asserted-by":"crossref","first-page":"4929","DOI":"10.1523\/JNEUROSCI.18-13-04929.1998","article-title":"Neurturin Exerts Potent Actions on Survival and Function of Midbrain Dopaminergic Neurons","volume":"18","author":"Horger","year":"1998","journal-title":"J. Neurosci."},{"key":"ref_157","doi-asserted-by":"crossref","first-page":"706","DOI":"10.1002\/ana.21032","article-title":"Delivery of Neurturin by AAV2 (Cere-120)-Mediated Gene Transfer Provides Structural and Functional Neuroprotection and Neurorestoration in Mptp-Treated Monkeys","volume":"60","author":"Kordower","year":"2006","journal-title":"Ann. Neurol."},{"key":"ref_158","doi-asserted-by":"crossref","first-page":"400","DOI":"10.1016\/S1474-4422(08)70065-6","article-title":"Safety and Tolerability of Intraputaminal Delivery of Cere-120 (Adeno-Associated Virus Serotype 2-Neurturin) to Patients with Idiopathic Parkinson\u2019s Disease: An Open-Label, Phase I Trial","volume":"7","author":"Marks","year":"2008","journal-title":"Lancet Neurol."},{"key":"ref_159","doi-asserted-by":"crossref","first-page":"1683","DOI":"10.1046\/j.0953-816x.2001.01542.x","article-title":"Neuroimmunophilin Ligands Exert Neuroregeneration and Neuroprotection in Midbrain Dopaminergic Neurons","volume":"13","author":"Guo","year":"2001","journal-title":"Eur. J. Neurosci."},{"key":"ref_160","doi-asserted-by":"crossref","first-page":"601","DOI":"10.1016\/S0306-4522(02)00314-7","article-title":"The Non-Immunosuppressive Immunophilin Ligand GPi-1046 Potently Stimulates Regenerating Axon Growth from Adult Mouse Dorsal Root Ganglia Cultured in Matrigel","volume":"114","author":"Khan","year":"2002","journal-title":"Neuroscience"},{"key":"ref_161","doi-asserted-by":"crossref","first-page":"421","DOI":"10.1038\/nm0497-421","article-title":"Neurotrophic Actions of Nonimmunosuppressive Analogues of Immunosuppressive Drugs Fk506, Rapamycin and Cyclosporin A","volume":"3","author":"Steiner","year":"1997","journal-title":"Nat. Med."},{"key":"ref_162","doi-asserted-by":"crossref","first-page":"250","DOI":"10.1016\/S0006-8993(03)02434-X","article-title":"Immunosuppressive (Fk506) and Non-Immunosuppressive (GPi1046) Immunophilin Ligands Activate Neurotrophic Factors in the Mouse Brain","volume":"970","author":"Tanaka","year":"2003","journal-title":"Brain Res."},{"key":"ref_163","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.neuroscience.2004.06.016","article-title":"Neuroimmunophilins: A Novel Drug Therapy for the Reversal of Neurodegenerative Disease?","volume":"128","author":"Poulter","year":"2004","journal-title":"Neuroscience"},{"key":"ref_164","doi-asserted-by":"crossref","unstructured":"Movement Disorder Society Task Force on Rating Scales for Parkinson\u2019s Disease (2003). The Unified Parkinson\u2019s Disease Rating Scale (Updrs): Status and Recommendations. Mov. Disord., 18, 738\u2013750.","DOI":"10.1002\/mds.10473"},{"key":"ref_165","doi-asserted-by":"crossref","first-page":"867","DOI":"10.1002\/mds.10248","article-title":"Systematic Evaluation of Rating Scales for Impairment and Disability in Parkinson\u2019s Disease","volume":"17","author":"Ramaker","year":"2002","journal-title":"Mov. Disord."},{"key":"ref_166","doi-asserted-by":"crossref","first-page":"41","DOI":"10.1002\/mds.21198","article-title":"Movement Disorder Society-Sponsored Revision of the Unified Parkinson\u2019s Disease Rating Scale (Mds-Updrs): Process, Format, and Clinimetric Testing Plan","volume":"22","author":"Goetz","year":"2007","journal-title":"Mov. Disord."},{"key":"ref_167","doi-asserted-by":"crossref","first-page":"S50","DOI":"10.1212\/WNL.66.10_suppl_4.S50","article-title":"Issues in Neuroprotection Clinical Trials in Parkinson\u2019s Disease","volume":"66","author":"Kieburtz","year":"2006","journal-title":"Neurology"},{"key":"ref_168","doi-asserted-by":"crossref","first-page":"171","DOI":"10.1111\/j.1749-6632.2003.tb07475.x","article-title":"Transgenic Models of Alpha-Synuclein Pathology: Past, Present, and Future","volume":"991","author":"Hashimoto","year":"2003","journal-title":"Ann. N. Y. Acad. Sci."},{"key":"ref_169","doi-asserted-by":"crossref","first-page":"308","DOI":"10.1002\/bies.10067","article-title":"Animal Models of Parkinson\u2019s Disease","volume":"24","author":"Betarbet","year":"2002","journal-title":"Bioessays"},{"key":"ref_170","doi-asserted-by":"crossref","first-page":"477","DOI":"10.1097\/WCO.0b013e32826388d6","article-title":"Clinical Trials for Neuroprotection in Parkinson\u2019s Disease: Overcoming Angst and Futility?","volume":"20","author":"Hung","year":"2007","journal-title":"Curr. Opin. Neurol."},{"key":"ref_171","doi-asserted-by":"crossref","first-page":"727","DOI":"10.1038\/nrn1199","article-title":"The Role of Alpha-Synuclein in Parkinson\u2019s Disease: Insights from Animal Models","volume":"4","author":"Maries","year":"2003","journal-title":"Nat. Rev. Neurosci."},{"key":"ref_172","doi-asserted-by":"crossref","first-page":"176","DOI":"10.1002\/ana.10613","article-title":"How Much Phenotypic Variation Can Be Attributed to Parkin Genotype?","volume":"54","author":"Lohmann","year":"2003","journal-title":"Ann. Neurol."},{"key":"ref_173","doi-asserted-by":"crossref","first-page":"1560","DOI":"10.1056\/NEJM200005253422103","article-title":"Association between Early-Onset Parkinson\u2019s Disease and Mutations in the Parkin Gene","volume":"342","author":"Lucking","year":"2000","journal-title":"N. Engl. J. Med."},{"key":"ref_174","first-page":"415","article-title":"A Common Lrrk2 Mutation in Idiopathic Parkinson\u2019s Disease","volume":"365","author":"Gilks","year":"2005","journal-title":"Lancet"},{"key":"ref_175","doi-asserted-by":"crossref","first-page":"672","DOI":"10.1086\/429256","article-title":"Identification of a Novel Lrrk2 Mutation Linked to Autosomal Dominant Parkinsonism: Evidence of a Common Founder across European Populations","volume":"76","author":"Kachergus","year":"2005","journal-title":"Am. J. Hum. Genet."},{"key":"ref_176","doi-asserted-by":"crossref","first-page":"131","DOI":"10.1002\/mds.25273","article-title":"Novel Nondopaminergic Targets for Motor Features of Parkinson\u2019s Disease: Review of Recent Trials","volume":"28","author":"Kalia","year":"2013","journal-title":"Mov. Disord."},{"key":"ref_177","doi-asserted-by":"crossref","first-page":"963","DOI":"10.1002\/ana.20682","article-title":"Nonsteroidal Antiinflammatory Drug Use and the Risk for Parkinson\u2019s Disease","volume":"58","author":"Chen","year":"2005","journal-title":"Ann. Neurol."},{"key":"ref_178","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.brainres.2004.02.083","article-title":"Simvastatin Prevents 1-Methyl-4-Phenyl-1,2,3,6-Tetrahydropyridine-Induced Striatal Dopamine Depletion and Protein Tyrosine Nitration in Mice","volume":"1037","author":"Selley","year":"2005","journal-title":"Brain Res."},{"key":"ref_179","doi-asserted-by":"crossref","first-page":"1908","DOI":"10.1053\/euhj.2002.3236","article-title":"Statins and Stroke: Evidence for Cholesterol-Independent Effects","volume":"23","author":"Taccardi","year":"2002","journal-title":"Eur. Heart J."},{"key":"ref_180","doi-asserted-by":"crossref","first-page":"1418","DOI":"10.1212\/01.wnl.0000286942.14552.51","article-title":"Statin Use and the Risk of Parkinson Disease","volume":"70","author":"Wahner","year":"2008","journal-title":"Neurology"},{"key":"ref_181","doi-asserted-by":"crossref","first-page":"998","DOI":"10.1093\/aje\/kwj283","article-title":"Serum Cholesterol Levels and the Risk of Parkinson\u2019s Disease","volume":"164","author":"Koudstaal","year":"2006","journal-title":"Am. J. Epidemiol."},{"key":"ref_182","doi-asserted-by":"crossref","first-page":"377","DOI":"10.1002\/mds.21290","article-title":"Lower Low-Density Lipoprotein Cholesterol Levels Are Associated with Parkinson\u2019s Disease","volume":"22","author":"Huang","year":"2007","journal-title":"Mov. Disord."},{"key":"ref_183","doi-asserted-by":"crossref","first-page":"101","DOI":"10.1046\/j.0022-3042.2001.00676.x","article-title":"Dietary Folate Deficiency and Elevated Homocysteine Levels Endanger Dopaminergic Neurons in Models of Parkinson\u2019s Disease","volume":"80","author":"Duan","year":"2002","journal-title":"J. Neurochem."},{"key":"ref_184","doi-asserted-by":"crossref","first-page":"14669","DOI":"10.1073\/pnas.251341998","article-title":"Minocycline Prevents Nigrostriatal Dopaminergic Neurodegeneration in the Mptp Model of Parkinson\u2019s Disease","volume":"98","author":"Du","year":"2001","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"ref_185","doi-asserted-by":"crossref","first-page":"187","DOI":"10.1016\/S0006-8993(01)02681-6","article-title":"Minocycline Inhibits Microglial Activation and Protects Nigral Cells after 6-Hydroxydopamine Injection into Mouse Striatum","volume":"909","author":"He","year":"2001","journal-title":"Brain Res."},{"key":"ref_186","doi-asserted-by":"crossref","first-page":"1763","DOI":"10.1523\/JNEUROSCI.22-05-01763.2002","article-title":"Blockade of Microglial Activation Is Neuroprotective in the 1-Methyl-4-Phenyl-1,2,3,6-Tetrahydropyridine Mouse Model of Parkinson Disease","volume":"22","author":"Wu","year":"2002","journal-title":"J. Neurosci."},{"key":"ref_187","doi-asserted-by":"crossref","first-page":"6858","DOI":"10.1073\/pnas.78.11.6858","article-title":"Uric Acid Provides an Antioxidant Defense in Humans Against Oxidant- and Radical-Caused Aging and Cancer: A Hypothesis","volume":"78","author":"Ames","year":"1981","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"ref_188","doi-asserted-by":"crossref","first-page":"716","DOI":"10.1001\/archneur.2008.65.6.nct70003","article-title":"Serum Urate As a Predictor of Clinical and Radiographic Progression in Parkinson Disease","volume":"65","author":"Schwarzschild","year":"2008","journal-title":"Arch. Neurol."},{"key":"ref_189","doi-asserted-by":"crossref","first-page":"831","DOI":"10.1093\/aje\/kwm385","article-title":"Diet, Urate, and Parkinson\u2019s Disease Risk in Men","volume":"167","author":"Gao","year":"2008","journal-title":"Am. J. Epidemiol."},{"key":"ref_190","doi-asserted-by":"crossref","unstructured":"Haywood, A.F., and Staveley, B.E. (2004). Parkin Counteracts Symptoms in a Drosophila Model of Parkinson\u2019s Disease. BMC Neurosci., 5.","DOI":"10.1186\/1471-2202-5-14"},{"key":"ref_191","doi-asserted-by":"crossref","first-page":"17510","DOI":"10.1073\/pnas.0405313101","article-title":"Lentiviral Vector Delivery of Parkin Prevents Dopaminergic Degeneration in an Alpha-Synuclein Rat Model of Parkinson\u2019s Disease","volume":"101","author":"Schneider","year":"2004","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"ref_192","doi-asserted-by":"crossref","first-page":"262","DOI":"10.1089\/hum.2005.16.262","article-title":"Parkin Gene Therapy for Alpha-Synucleinopathy: A Rat Model of Parkinson\u2019s Disease","volume":"16","author":"Yamada","year":"2005","journal-title":"Hum. Gene Ther."},{"key":"ref_193","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1186\/1756-6606-1-17","article-title":"Lysosomal Enzyme Cathepsin D Protects Against Alpha-Synuclein Aggregation and Toxicity","volume":"1","author":"Qiao","year":"2008","journal-title":"Mol. Brain"},{"key":"ref_194","doi-asserted-by":"crossref","first-page":"857","DOI":"10.1016\/j.neuron.2005.05.010","article-title":"Effects of Alpha-Synuclein Immunization in a Mouse Model of Parkinson\u2019s Disease","volume":"46","author":"Masliah","year":"2005","journal-title":"Neuron"},{"key":"ref_195","doi-asserted-by":"crossref","first-page":"657","DOI":"10.1038\/nn1443","article-title":"Alpha-Synuclein Phosphorylation Controls Neurotoxicity and Inclusion Formation in a Drosophila Model of Parkinson Disease","volume":"8","author":"Chen","year":"2005","journal-title":"Nat. Neurosci."},{"key":"ref_196","doi-asserted-by":"crossref","first-page":"5544","DOI":"10.1523\/JNEUROSCI.0482-05.2005","article-title":"Alpha-Synuclein Phosphorylation Enhances Eosinophilic Cytoplasmic Inclusion Formation in Sh-Sy5y Cells","volume":"25","author":"Smith","year":"2005","journal-title":"J. Neurosci."},{"key":"ref_197","doi-asserted-by":"crossref","first-page":"18344","DOI":"10.1074\/jbc.M000206200","article-title":"Dityrosine Cross-Linking Promotes Formation of Stable Alpha-Synuclein Polymers. Implication of Nitrative and Oxidative Stress in the Pathogenesis of Neurodegenerative Synucleinopathies","volume":"275","author":"Souza","year":"2000","journal-title":"J. Biol. Chem."},{"key":"ref_198","doi-asserted-by":"crossref","first-page":"157","DOI":"10.1523\/JNEUROSCI.1833-10.2011","article-title":"Novel Regulation of Parkin Function through c-Abl-Mediated Tyrosine Phosphorylation: Implications for Parkinson\u2019s Disease","volume":"31","author":"Imam","year":"2011","journal-title":"J. Neurosci."},{"key":"ref_199","doi-asserted-by":"crossref","first-page":"3315","DOI":"10.1093\/hmg\/ddt192","article-title":"Nilotinib Reverses Loss of Dopamine Neurons and Improves Motor Behavior Via Autophagic Degradation of Alpha-Synuclein in Parkinson\u2019s Disease Models","volume":"22","author":"Hebron","year":"2013","journal-title":"Hum. Mol. Genet."},{"key":"ref_200","doi-asserted-by":"crossref","first-page":"16691","DOI":"10.1073\/pnas.1006083107","article-title":"Phosphorylation by the c-Abl Protein Tyrosine Kinase Inhibits Parkin\u2019s Ubiquitination and Protective Function","volume":"107","author":"Ko","year":"2010","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"ref_201","doi-asserted-by":"crossref","first-page":"1664","DOI":"10.1073\/pnas.1214330110","article-title":"Explaining Why Gleevec Is a Specific and Potent Inhibitor of Abl Kinase","volume":"110","author":"Lin","year":"2013","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"ref_202","doi-asserted-by":"crossref","first-page":"1956","DOI":"10.1016\/j.clinthera.2008.11.014","article-title":"Nilotinib: A Second-Generation Tyrosine Kinase Inhibitor for the Treatment of Chronic Myelogenous Leukemia","volume":"30","author":"Deremer","year":"2008","journal-title":"Clin. Ther."},{"key":"ref_203","doi-asserted-by":"crossref","unstructured":"Imam, S.Z., Trickler, W., Kimura, S., Binienda, Z.K., Paule, M.G., Slikker, W., Li, S., Clark, R.A., and Ali, S.F. (2013). Neuroprotective Efficacy of a New Brain-Penetrating c-Abl Inhibitor in a Murine Parkinson\u2019s Disease Model. PLoS ONE, 8.","DOI":"10.1371\/journal.pone.0065129"},{"key":"ref_204","doi-asserted-by":"crossref","first-page":"190","DOI":"10.1002\/mds.20324","article-title":"Sydney Multicenter Study of Parkinson\u2019s Disease: Non-l-Dopa-Responsive Problems Dominate at 15 Years","volume":"20","author":"Hely","year":"2005","journal-title":"Mov. Disord."},{"key":"ref_205","doi-asserted-by":"crossref","first-page":"294","DOI":"10.1016\/j.amjopharm.2010.08.002","article-title":"Clinical Review of Treatment Options for Select Nonmotor Symptoms of Parkinson\u2019s Disease","volume":"8","author":"Wood","year":"2010","journal-title":"Am. J. Geriatr. Pharmacother."},{"key":"ref_206","doi-asserted-by":"crossref","first-page":"886","DOI":"10.1212\/01.wnl.0000336340.89821.b3","article-title":"A Controlled Trial of Antidepressants in Patients with Parkinson Disease and Depression","volume":"72","author":"Menza","year":"2009","journal-title":"Neurology"},{"key":"ref_207","doi-asserted-by":"crossref","first-page":"1436","DOI":"10.1126\/science.2402638","article-title":"Reversal of Experimental Parkinsonism by Lesions of the Subthalamic Nucleus","volume":"249","author":"Bergman","year":"1990","journal-title":"Science"},{"key":"ref_208","doi-asserted-by":"crossref","first-page":"351","DOI":"10.1016\/j.neuroscience.2006.09.019","article-title":"Glutamate and GABA Receptors and Transporters in the Basal Ganglia: What Does Their Subsynaptic Localization Reveal about Their Function?","volume":"143","author":"Galvan","year":"2006","journal-title":"Neuroscience"},{"key":"ref_209","doi-asserted-by":"crossref","first-page":"165","DOI":"10.1001\/archneurol.2010.260","article-title":"Deep Brain Stimulation for Parkinson Disease: An Expert Consensus and Review of Key Issues","volume":"68","author":"Bronstein","year":"2011","journal-title":"Arch. Neurol."},{"key":"ref_210","first-page":"142","article-title":"Deep Brain Stimulation for Parkinson\u2019s Disease: Patient Selection and Motor Outcomes","volume":"89","author":"Chang","year":"2006","journal-title":"Med. Health Rhode Isl."},{"key":"ref_211","doi-asserted-by":"crossref","first-page":"554","DOI":"10.1001\/archneur.62.4.554","article-title":"Pallidal vs. Subthalamic Nucleus Deep Brain Stimulation in Parkinson Disease","volume":"62","author":"Anderson","year":"2005","journal-title":"Arch. Neurol."},{"key":"ref_212","doi-asserted-by":"crossref","first-page":"143","DOI":"10.1016\/j.parkreldis.2005.10.007","article-title":"Chronic Stimulation of the Subthalamic Nucleus Increases Daily on-Time without Dyskinesia in Advanced Parkinson\u2019s Disease","volume":"12","author":"Portman","year":"2006","journal-title":"Parkinsonism Relat. Disord."},{"key":"ref_213","doi-asserted-by":"crossref","first-page":"2240","DOI":"10.1093\/brain\/awh571","article-title":"Bilateral Deep Brain Stimulation in Parkinson\u2019s Disease: A Multicentre Study with 4 Years Follow-up","volume":"128","author":"Obeso","year":"2005","journal-title":"Brain"},{"key":"ref_214","doi-asserted-by":"crossref","first-page":"956","DOI":"10.3171\/jns.2005.103.6.0956","article-title":"Deep Brain Stimulation in Parkinson Disease: A Metaanalysis of Patient Outcomes","volume":"103","author":"Weaver","year":"2005","journal-title":"J. Neurosurg."},{"key":"ref_215","doi-asserted-by":"crossref","first-page":"136","DOI":"10.1159\/000093213","article-title":"Chronic Deep Brain Stimulation of the Subthalamic Nucleus for Parkinson\u2019s Disease: Effects on Cognition, Mood, Anxiety and Personality Traits","volume":"55","author":"Castelli","year":"2006","journal-title":"Eur. Neurol."},{"key":"ref_216","doi-asserted-by":"crossref","first-page":"450","DOI":"10.1136\/jnnp.2005.078659","article-title":"Clinical and Neuropsychological Follow up at 12 Months in Patients with Complicated Parkinson\u2019s Disease Treated with Subcutaneous Apomorphine Infusion or Deep Brain Stimulation of the Subthalamic Nucleus","volume":"77","author":"Siri","year":"2006","journal-title":"J. Neurol. Neurosurg. Psychiatry"},{"key":"ref_217","first-page":"202","article-title":"Subthalamic Nucleus Stimulation Induces Deficits in Decoding Emotional Facial Expressions in Parkinson\u2019s Disease","volume":"75","author":"Dujardin","year":"2004","journal-title":"J. Neurol. Neurosurg. Psychiatry"},{"key":"ref_218","doi-asserted-by":"crossref","first-page":"603","DOI":"10.1007\/s004150170139","article-title":"Influence of Chronic Bilateral Stimulation of the Subthalamic Nucleus on Cognitive Function in Parkinson\u2019s Disease","volume":"248","author":"Dujardin","year":"2001","journal-title":"J. Neurol."},{"key":"ref_219","doi-asserted-by":"crossref","first-page":"415","DOI":"10.1080\/02688690801971667","article-title":"Prospective Randomized 1-Year Follow-up Comparison of Bilateral Subthalamotomy versus Bilateral Subthalamic Stimulation and the Combination of Both in Parkinson\u2019s Disease Patients: A Pilot Study","volume":"22","author":"Merello","year":"2008","journal-title":"Br. J. Neurosurg."},{"key":"ref_220","doi-asserted-by":"crossref","first-page":"1640","DOI":"10.1136\/jnnp.2005.063206","article-title":"Stimulation of the Subthalamic Nucleus in Parkinson\u2019s Disease: A 5 Year Follow up","volume":"76","author":"Schupbach","year":"2005","journal-title":"J. Neurol. Neurosurg. Psychiatry"},{"key":"ref_221","doi-asserted-by":"crossref","first-page":"176","DOI":"10.1007\/s00415-005-0628-z","article-title":"Unilateral Pallidotomy versus Bilateral Subthalamic Nucleus Stimulation in PD\u2014A Comparison of Neuropsychological Effects","volume":"252","author":"Smeding","year":"2005","journal-title":"J. Neurol."},{"key":"ref_222","doi-asserted-by":"crossref","first-page":"754","DOI":"10.1136\/jnnp.2007.140012","article-title":"Predictors of Cognitive and Psychosocial Outcome after STN DBS in Parkinson\u2019s Disease","volume":"82","author":"Smeding","year":"2011","journal-title":"J. Neurol. Neurosurg. Psychiatry"},{"key":"ref_223","doi-asserted-by":"crossref","first-page":"1830","DOI":"10.1212\/01.wnl.0000234881.77830.66","article-title":"Neuropsychological Effects of Bilateral STN Stimulation in Parkinson Disease: A Controlled Study","volume":"66","author":"Smeding","year":"2006","journal-title":"Neurology"},{"key":"ref_224","doi-asserted-by":"crossref","first-page":"S113","DOI":"10.1139\/y92-252","article-title":"Changes in the Glucose Transporter of Brain Capillaries","volume":"70","author":"Harik","year":"1992","journal-title":"Can. J. Physiol. Pharmacol."},{"key":"ref_225","doi-asserted-by":"crossref","first-page":"1427","DOI":"10.1212\/01.WNL.0000032756.14298.18","article-title":"Effect on Mood of Subthalamic DBS for Parkinson\u2019s Disease: A Consecutive Series of 24 Patients","volume":"59","author":"Berney","year":"2002","journal-title":"Neurology"},{"key":"ref_226","doi-asserted-by":"crossref","first-page":"1084","DOI":"10.1002\/mds.10198","article-title":"Depression Leading to Attempted Suicide after Bilateral Subthalamic Nucleus Stimulation for Parkinson\u2019s Disease","volume":"17","author":"Doshi","year":"2002","journal-title":"Mov. Disord."},{"key":"ref_227","doi-asserted-by":"crossref","first-page":"834","DOI":"10.1136\/jnnp.2002.009803","article-title":"Long Term Effects of Bilateral Subthalamic Nucleus Stimulation on Cognitive Function, Mood, and Behaviour in Parkinson\u2019s Disease","volume":"75","author":"Funkiewiez","year":"2004","journal-title":"J. Neurol. Neurosurg. Psychiatry"},{"key":"ref_228","doi-asserted-by":"crossref","first-page":"586","DOI":"10.1002\/ana.21596","article-title":"Cognition and Mood in Parkinson\u2019s Disease in Subthalamic Nucleus versus Globus Pallidus Interna Deep Brain Stimulation: The Compare Trial","volume":"65","author":"Okun","year":"2009","journal-title":"Ann. Neurol."},{"key":"ref_229","doi-asserted-by":"crossref","first-page":"1584","DOI":"10.1136\/jnnp.74.11.1584","article-title":"Mood Changes with Deep Brain Stimulation of STN and GPi: Results of a Pilot Study","volume":"74","author":"Okun","year":"2003","journal-title":"J. Neurol. Neurosurg. Psychiatry"},{"key":"ref_230","doi-asserted-by":"crossref","first-page":"2720","DOI":"10.1093\/brain\/awn214","article-title":"A Multicentre Study on Suicide Outcomes Following Subthalamic Stimulation for Parkinson\u2019s Disease","volume":"131","author":"Voon","year":"2008","journal-title":"Brain"},{"key":"ref_231","doi-asserted-by":"crossref","first-page":"578","DOI":"10.1002\/mds.22735","article-title":"Long-Term Results of a Multicenter Study on Subthalamic and Pallidal Stimulation in Parkinson\u2019s Disease","volume":"25","author":"Moro","year":"2010","journal-title":"Mov. Disord."},{"key":"ref_232","doi-asserted-by":"crossref","first-page":"315","DOI":"10.1136\/jnnp.2009.184127","article-title":"Impact of STN-DBS on Life and Health Satisfaction in Patients with Parkinson\u2019s Disease","volume":"81","author":"Ferrara","year":"2010","journal-title":"J. Neurol. Neurosurg. Psychiatry"},{"key":"ref_233","doi-asserted-by":"crossref","first-page":"1091","DOI":"10.1002\/mds.23012","article-title":"Characterization of Lewy Body Pathology in 12- And 16-Year-Old Intrastriatal Mesencephalic Grafts Surviving in a Patient with Parkinson\u2019s Disease","volume":"25","author":"Li","year":"2010","journal-title":"Mov. Disord."},{"key":"ref_234","doi-asserted-by":"crossref","first-page":"295","DOI":"10.1016\/S0079-6123(10)84015-4","article-title":"Neural Grafting in Parkinson\u2019s Disease Unraveling the Mechanisms Underlying Graft-Induced Dyskinesia","volume":"184","author":"Lane","year":"2010","journal-title":"Prog. Brain Res."},{"key":"ref_235","doi-asserted-by":"crossref","first-page":"334","DOI":"10.1016\/j.nbd.2005.11.011","article-title":"The Impact of Graft Size on the Development of Dyskinesia Following Intrastriatal Grafting of Embryonic Dopamine Neurons in the Rat","volume":"22","author":"Lane","year":"2006","journal-title":"Neurobiol. Dis."},{"key":"ref_236","doi-asserted-by":"crossref","first-page":"38ra46","DOI":"10.1126\/scitranslmed.3000976","article-title":"Serotonergic Neurons Mediate Dyskinesia Side Effects in Parkinson\u2019s Patients with Neural Transplants","volume":"2","author":"Politis","year":"2010","journal-title":"Sci. Transl. Med."},{"key":"ref_237","first-page":"540","article-title":"Gene Therapeutic Strategies for Neurodegenerative Diseases","volume":"2","author":"Baekelandt","year":"2000","journal-title":"Curr. Opin. Mol. Ther."},{"key":"ref_238","doi-asserted-by":"crossref","first-page":"82","DOI":"10.1016\/S0006-8993(00)02915-2","article-title":"Towards a Neuroprotective Gene Therapy for Parkinson\u2019s Disease: Use of Adenovirus, AAV and Lentivirus Vectors for Gene Transfer of Gdnf to the Nigrostriatal System in the Rat Parkinson Model","volume":"886","author":"Bjorklund","year":"2000","journal-title":"Brain Res."},{"key":"ref_239","doi-asserted-by":"crossref","first-page":"177","DOI":"10.2165\/11533740-000000000-00000","article-title":"Gene Therapy in Parkinson\u2019s Disease: Rationale and Current Status","volume":"24","author":"Feng","year":"2010","journal-title":"CNS Drugs"},{"key":"ref_240","doi-asserted-by":"crossref","first-page":"2097","DOI":"10.1016\/S0140-6736(07)60982-9","article-title":"Safety and Tolerability of Gene Therapy with an Adeno-Associated Virus (AAV) Borne GAD Gene for Parkinson\u2019s Disease: An Open Label, Phase I Trial","volume":"369","author":"Kaplitt","year":"2007","journal-title":"Lancet"},{"key":"ref_241","doi-asserted-by":"crossref","first-page":"309","DOI":"10.1016\/S1474-4422(11)70039-4","article-title":"AAV2-GAD Gene Therapy for Advanced Parkinson\u2019s Disease: A Double-Blind, Sham-Surgery Controlled, Randomised Trial","volume":"10","author":"Lewitt","year":"2011","journal-title":"Lancet Neurol."},{"key":"ref_242","doi-asserted-by":"crossref","first-page":"1662","DOI":"10.1212\/WNL.0b013e3181c29356","article-title":"Safety and Tolerability of Putaminal Aadc Gene Therapy for Parkinson Disease","volume":"73","author":"Christine","year":"2009","journal-title":"Neurology"},{"key":"ref_243","doi-asserted-by":"crossref","first-page":"1980","DOI":"10.1212\/01.wnl.0000312381.29287.ff","article-title":"Results from a Phase I Safety Trial of Haadc Gene Therapy for Parkinson Disease","volume":"70","author":"Eberling","year":"2008","journal-title":"Neurology"},{"key":"ref_244","doi-asserted-by":"crossref","first-page":"2ra4","DOI":"10.1126\/scitranslmed.3000130","article-title":"Dopamine Gene Therapy for Parkinson\u2019s Disease in a Nonhuman Primate without Associated Dyskinesia","volume":"1","author":"Jarraya","year":"2009","journal-title":"Sci. Transl. Med."},{"key":"ref_245","doi-asserted-by":"crossref","first-page":"1374","DOI":"10.1212\/01.wnl.0000343512.36654.41","article-title":"A New Sensitive Imaging Biomarker for Parkinson Disease?","volume":"72","author":"Lang","year":"2009","journal-title":"Neurology"},{"key":"ref_246","doi-asserted-by":"crossref","first-page":"S51","DOI":"10.1212\/WNL.0b013e318199049e","article-title":"\u201cDisease-Modification\u201d Trials in Parkinson Disease: Target Populations, Endpoints and Study Design","volume":"72","author":"Rascol","year":"2009","journal-title":"Neurology"},{"key":"ref_247","doi-asserted-by":"crossref","first-page":"493","DOI":"10.1016\/0021-9681(75)90058-2","article-title":"Olfactory Function in Patients with Parkinson\u2019s Disease","volume":"28","author":"Ansari","year":"1975","journal-title":"J. Chronic Dis."},{"key":"ref_248","doi-asserted-by":"crossref","first-page":"839","DOI":"10.1002\/mds.21413","article-title":"Olfactory Loss May Be a First Sign of Idiopathic Parkinson\u2019s Disease","volume":"22","author":"Haehner","year":"2007","journal-title":"Mov. Disord."},{"key":"ref_249","doi-asserted-by":"crossref","first-page":"1773","DOI":"10.1586\/ern.09.115","article-title":"Olfactory Dysfunction As a Diagnostic Marker for Parkinson\u2019s Disease","volume":"9","author":"Haehner","year":"2009","journal-title":"Expert Rev. Neurother."},{"key":"ref_250","doi-asserted-by":"crossref","first-page":"661","DOI":"10.2217\/bmm.10.95","article-title":"Olfaction As a Biomarker in Parkinson\u2019s Disease","volume":"4","author":"Morley","year":"2010","journal-title":"Biomark. Med."},{"key":"ref_251","doi-asserted-by":"crossref","first-page":"1237","DOI":"10.1212\/WNL.38.8.1237","article-title":"Olfactory Dysfunction in Parkinsonism: A General Deficit Unrelated to Neurologic Signs, Disease Stage, or Disease Duration","volume":"38","author":"Doty","year":"1988","journal-title":"Neurology"},{"key":"ref_252","doi-asserted-by":"crossref","first-page":"871","DOI":"10.1212\/WNL.61.6.871-a","article-title":"Olfactory Function in Essential Tremor: A Deficit Unrelated to Disease Duration or Severity","volume":"61","author":"Hawkes","year":"2003","journal-title":"Neurology"},{"key":"ref_253","doi-asserted-by":"crossref","first-page":"436","DOI":"10.1136\/jnnp.62.5.436","article-title":"Olfactory Dysfunction in Parkinson\u2019s Disease","volume":"62","author":"Hawkes","year":"1997","journal-title":"J. Neurol. Neurosurg. Psychiatry"},{"key":"ref_254","doi-asserted-by":"crossref","first-page":"169","DOI":"10.1002\/ana.20180","article-title":"The Preclinical Detection of Parkinson\u2019s Disease: Ready for Prime Time?","volume":"56","author":"Stern","year":"2004","journal-title":"Ann. Neurol."},{"key":"ref_255","doi-asserted-by":"crossref","first-page":"521","DOI":"10.1054\/jocn.2001.1071","article-title":"Olfactory Function in Parkinsonian Syndromes","volume":"9","author":"Muller","year":"2002","journal-title":"J. Clin. Neurosci."},{"key":"ref_256","doi-asserted-by":"crossref","first-page":"677","DOI":"10.3174\/ajnr.A2350","article-title":"Association of Olfactory Bulb Volume and Olfactory Sulcus Depth with Olfactory Function in Patients with Parkinson Disease","volume":"32","author":"Wang","year":"2011","journal-title":"AJNR Am. J. Neuroradiol."},{"key":"ref_257","doi-asserted-by":"crossref","first-page":"906","DOI":"10.1002\/mds.22464","article-title":"Biopsies of Olfactory Epithelium in Patients with Parkinson\u2019s Disease","volume":"24","author":"Witt","year":"2009","journal-title":"Mov. Disord."},{"key":"ref_258","doi-asserted-by":"crossref","first-page":"687","DOI":"10.1002\/mds.10713","article-title":"A 100% Increase of Dopaminergic Cells in the Olfactory Bulb May Explain Hyposmia in Parkinson\u2019s Disease","volume":"19","author":"Huisman","year":"2004","journal-title":"Mov. Disord."},{"key":"ref_259","first-page":"1378","article-title":"Relationship between Caffeine Intake and Parkinson Disease","volume":"284","author":"Ross","year":"2000","journal-title":"JAMA"},{"key":"ref_260","doi-asserted-by":"crossref","first-page":"39","DOI":"10.1093\/chemse\/22.1.39","article-title":"\u2018Sniffin\u2019 Sticks\u2019: Olfactory Performance Assessed by the Combined Testing of Odor Identification, Odor Discrimination and Olfactory Threshold","volume":"22","author":"Hummel","year":"1997","journal-title":"Chem. Senses"},{"key":"ref_261","doi-asserted-by":"crossref","first-page":"247","DOI":"10.1111\/j.1600-0404.1995.tb06998.x","article-title":"Olfactory Function in Atypical Parkinsonian Syndromes","volume":"91","author":"Wenning","year":"1995","journal-title":"Acta Neurol. Scand."},{"key":"ref_262","doi-asserted-by":"crossref","first-page":"382","DOI":"10.1097\/NRL.0b013e31815a351a","article-title":"Sniffing out Parkinson Disease: Can Olfactory Testing Differentiate Parkinsonian Disorders?","volume":"13","author":"Mckinnon","year":"2007","journal-title":"Neurologist"},{"key":"ref_263","doi-asserted-by":"crossref","first-page":"516","DOI":"10.1016\/j.parkreldis.2008.12.009","article-title":"Olfactory Dysfunction in Pure Autonomic Failure: Implications for the Pathogenesis of Lewy Body Diseases","volume":"15","author":"Goldstein","year":"2009","journal-title":"Parkinsonism Relat. Disord."},{"key":"ref_264","doi-asserted-by":"crossref","first-page":"364","DOI":"10.1002\/mds.10379","article-title":"Olfaction in Neurodegenerative Disorder","volume":"18","author":"Hawkes","year":"2003","journal-title":"Mov. Disord."},{"key":"ref_265","doi-asserted-by":"crossref","first-page":"88","DOI":"10.1007\/PL00007803","article-title":"Olfaction in Parkinson\u2019s Disease: Methods of Assessment and Clinical Relevance","volume":"247","author":"Liberini","year":"2000","journal-title":"J. Neurol."},{"key":"ref_266","doi-asserted-by":"crossref","first-page":"667","DOI":"10.1136\/jnnp.2008.155895","article-title":"Olfactory Impairment Is More Marked in Patients with Mild Dementia with Lewy Bodies Than Those with Mild Alzheimer Disease","volume":"80","author":"Williams","year":"2009","journal-title":"J. Neurol. Neurosurg. Psychiatry"},{"key":"ref_267","doi-asserted-by":"crossref","first-page":"S21","DOI":"10.1212\/WNL.0b013e318198df97","article-title":"Can We Image Premotor Parkinson Disease?","volume":"72","author":"Marek","year":"2009","journal-title":"Neurology"},{"key":"ref_268","doi-asserted-by":"crossref","first-page":"284","DOI":"10.1016\/S1474-4422(04)00736-7","article-title":"Functional Brain Imaging in the Differential Diagnosis of Parkinson\u2019s Disease","volume":"3","author":"Piccini","year":"2004","journal-title":"Lancet Neurol."},{"key":"ref_269","doi-asserted-by":"crossref","first-page":"5","DOI":"10.1136\/jnnp.2008.157370","article-title":"The Role of Dat-SPECT in Movement Disorders","volume":"81","author":"Kagi","year":"2010","journal-title":"J. Neurol. Neurosurg. Psychiatry"},{"key":"ref_270","doi-asserted-by":"crossref","first-page":"591","DOI":"10.1002\/ana.20834","article-title":"The Parkinson\u2019s Complex: Parkinsonism Is Just the Tip of the Iceberg","volume":"59","author":"Langston","year":"2006","journal-title":"Ann. Neurol."},{"key":"ref_271","doi-asserted-by":"crossref","first-page":"7","DOI":"10.1016\/S1474-4422(06)70661-5","article-title":"Movement Disorders: Advances on Many Fronts","volume":"6","author":"Tolosa","year":"2007","journal-title":"Lancet Neurol."},{"key":"ref_272","doi-asserted-by":"crossref","first-page":"S2","DOI":"10.1016\/j.parkreldis.2007.06.007","article-title":"The Premotor Phase of Parkinson\u2019s Disease","volume":"13","author":"Tolosa","year":"2007","journal-title":"Parkinsonism Relat. Disord."},{"key":"ref_273","doi-asserted-by":"crossref","first-page":"173","DOI":"10.1002\/ana.20160","article-title":"Idiopathic Hyposmia As a Preclinical Sign of Parkinson\u2019s Disease","volume":"56","author":"Ponsen","year":"2004","journal-title":"Ann. Neurol."},{"key":"ref_274","first-page":"126","article-title":"Combination Of \u2018Idiopathic\u2019 Rem Sleep Behaviour Disorder and Olfactory Dysfunction As Possible Indicator for Alpha-Synucleinopathy Demonstrated by Dopamine Transporter Fp-Cit-SPECT","volume":"128","author":"Doerr","year":"2005","journal-title":"Brain"},{"key":"ref_275","doi-asserted-by":"crossref","first-page":"404","DOI":"10.1016\/j.nbd.2005.08.002","article-title":"In Vivo Imaging of Microglial Activation with [11c](R)-Pk11195 PET in Idiopathic Parkinson\u2019s Disease","volume":"21","author":"Gerhard","year":"2006","journal-title":"Neurobiol. Dis."},{"key":"ref_276","doi-asserted-by":"crossref","first-page":"382","DOI":"10.1016\/S1474-4422(09)70062-6","article-title":"Neuroinflammation in Parkinson\u2019s Disease: A Target for Neuroprotection?","volume":"8","author":"Hirsch","year":"2009","journal-title":"Lancet Neurol."},{"key":"ref_277","doi-asserted-by":"crossref","first-page":"168","DOI":"10.1002\/ana.20338","article-title":"Microglial Activation and Dopamine Terminal Loss in Early Parkinson\u2019s Disease","volume":"57","author":"Ouchi","year":"2005","journal-title":"Ann. Neurol."},{"key":"ref_278","doi-asserted-by":"crossref","first-page":"1841","DOI":"10.1586\/14737175.8.12.1841","article-title":"The Search for Biomarkers in Parkinson\u2019s Disease: A Critical Review","volume":"8","author":"Antoniades","year":"2008","journal-title":"Expert Rev. Neurother."},{"key":"ref_279","doi-asserted-by":"crossref","first-page":"925","DOI":"10.1586\/ern.10.54","article-title":"Using \u2018Omics\u2019 to Define Pathogenesis and Biomarkers of Parkinson\u2019s Disease","volume":"10","author":"Caudle","year":"2010","journal-title":"Expert Rev. Neurother."},{"key":"ref_280","doi-asserted-by":"crossref","first-page":"1181","DOI":"10.1080\/004982599238047","article-title":"\u2018Metabonomics\u2019: Understanding the Metabolic Responses of Living Systems to Pathophysiological Stimuli Via Multivariate Statistical Analysis of Biological Nmr Spectroscopic Data","volume":"29","author":"Nicholson","year":"1999","journal-title":"Xenobiotica"},{"key":"ref_281","doi-asserted-by":"crossref","first-page":"668","DOI":"10.1038\/nrd1157","article-title":"Opinion: Understanding \u2018Global\u2019 Systems Biology: Metabonomics and the Continuum of Metabolism","volume":"2","author":"Nicholson","year":"2003","journal-title":"Nat. Rev. Drug Discov."},{"key":"ref_282","doi-asserted-by":"crossref","first-page":"358","DOI":"10.1016\/j.nurx.2006.05.004","article-title":"The Application of Nmr-Based Metabonomics in Neurological Disorders","volume":"3","author":"Holmes","year":"2006","journal-title":"Neurorx"},{"key":"ref_283","doi-asserted-by":"crossref","first-page":"294","DOI":"10.1016\/j.neulet.2005.02.030","article-title":"Skin and Platelet Alpha-Synuclein As Peripheral Biomarkers of Parkinson\u2019s Disease","volume":"381","author":"Michell","year":"2005","journal-title":"Neurosci. Lett."},{"key":"ref_284","doi-asserted-by":"crossref","first-page":"10","DOI":"10.1007\/s11306-008-0111-9","article-title":"Metabolomic Analysis of Urine and Serum in Parkinson\u2019s Disease","volume":"4","author":"Michell","year":"2008","journal-title":"Metabolomics"},{"key":"ref_285","doi-asserted-by":"crossref","first-page":"389","DOI":"10.1093\/brain\/awm304","article-title":"Metabolomic Profiling to Develop Blood Biomarkers for Parkinson\u2019s Disease","volume":"131","author":"Bogdanov","year":"2008","journal-title":"Brain"},{"key":"ref_286","doi-asserted-by":"crossref","first-page":"473","DOI":"10.1111\/j.1749-6632.1987.tb23695.x","article-title":"Intracerebral Grafting of Dopamine Neurons. Experimental Basis for Clinical Trials in Patients with Parkinson\u2019s Disease","volume":"495","author":"Brundin","year":"1987","journal-title":"Ann. N. Y. Acad. Sci."},{"key":"ref_287","doi-asserted-by":"crossref","first-page":"539","DOI":"10.1016\/j.stem.2014.09.016","article-title":"Developing Stem Cell Therapies for Parkinson\u2019s Disease: Waiting Until the Time Is Right","volume":"15","author":"Barker","year":"2014","journal-title":"Cell Stem Cell"},{"key":"ref_288","doi-asserted-by":"crossref","first-page":"102","DOI":"10.1002\/cne.22033","article-title":"Transplantation of Subventricular Zone Neural Precursors Induces an Endogenous Precursor Cell Response in a Rat Model of Parkinson\u2019s Disease","volume":"515","author":"Madhavan","year":"2009","journal-title":"J. Comp. Neurol."},{"key":"ref_289","doi-asserted-by":"crossref","first-page":"S128","DOI":"10.1016\/S1353-8020(13)70031-2","article-title":"The Promises of Stem Cells: Stem Cell Therapy for Movement Disorders","volume":"20","author":"Mochizuki","year":"2014","journal-title":"Parkinsonism Relat. Disord."},{"key":"ref_290","doi-asserted-by":"crossref","first-page":"9703","DOI":"10.1073\/pnas.1016443108","article-title":"Es Cell-Derived Renewable and Functional Midbrain Dopaminergic Progenitors","volume":"108","author":"Chung","year":"2011","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"ref_291","doi-asserted-by":"crossref","first-page":"703","DOI":"10.1016\/j.celrep.2012.04.009","article-title":"Generation of Regionally Specified Neural Progenitors and Functional Neurons from Human Embryonic Stem Cells under Defined Conditions","volume":"1","author":"Kirkeby","year":"2012","journal-title":"Cell Rep."},{"key":"ref_292","doi-asserted-by":"crossref","first-page":"547","DOI":"10.1038\/nature10648","article-title":"Dopamine Neurons Derived from Human Es Cells Efficiently Engraft in Animal Models of Parkinson\u2019s Disease","volume":"480","author":"Kriks","year":"2011","journal-title":"Nature"},{"key":"ref_293","doi-asserted-by":"crossref","unstructured":"Zhu, B., Caldwell, M., and Song, B. (2016). Development of Stem Cell-Based Therapies for Parkinson\u2019s Disease. Int. J. Neurosci.","DOI":"10.3109\/00207454.2016.1148034"},{"key":"ref_294","doi-asserted-by":"crossref","first-page":"260","DOI":"10.1016\/j.tips.2009.03.001","article-title":"Prospects of Stem Cell Therapy for Replacing Dopamine Neurons in Parkinson\u2019s Disease","volume":"30","author":"Lindvall","year":"2009","journal-title":"Trends Pharmacol. Sci."},{"key":"ref_295","doi-asserted-by":"crossref","first-page":"685","DOI":"10.1007\/s12015-013-9443-6","article-title":"Progress in Stem Cell Therapy for Major Human Neurological Disorders","volume":"9","author":"Revilla","year":"2013","journal-title":"Stem Cell Rev."},{"key":"ref_296","doi-asserted-by":"crossref","first-page":"2326","DOI":"10.1172\/JCI45794","article-title":"Protein-Based Human Ips Cells Efficiently Generate Functional Dopamine Neurons and Can Treat a Rat Model of Parkinson Disease","volume":"121","author":"Rhee","year":"2011","journal-title":"J. Clin. Investig."},{"key":"ref_297","doi-asserted-by":"crossref","first-page":"267","DOI":"10.2217\/rme.10.3","article-title":"Stem Cell-Derived Dopamine Neurons for Brain Repair in Parkinson\u2019s Disease","volume":"5","author":"Gates","year":"2010","journal-title":"Regen. Med."},{"key":"ref_298","doi-asserted-by":"crossref","unstructured":"Foldes, A., Kadar, K., Keremi, B., Zsembery, A., Gyires, K., Zadori, Z.S., and Varga, G. (2016). Mesenchymal Stem Cells of Dental Origin\u2014Their Potential for Anti-Inflammatory and Regenerative Actions in Brain and Gut Damage. Curr. Neuropharmacol., 14.","DOI":"10.2174\/1570159X14666160121115210"},{"key":"ref_299","doi-asserted-by":"crossref","first-page":"965","DOI":"10.1038\/mt.2016.12","article-title":"Human Mesenchymal Stem Cells Genetically Engineered to Overexpress Brain-Derived Neurotrophic Factor Improve Outcomes in Huntington\u2019s Disease Mouse Models","volume":"24","author":"Pollock","year":"2016","journal-title":"Mol. Ther."},{"key":"ref_300","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1016\/j.expneurol.2013.03.016","article-title":"Mesenchymal Stem Cells and Neuroregeneration in Parkinson\u2019s Disease","volume":"247","author":"Bohn","year":"2013","journal-title":"Exp. Neurol."},{"key":"ref_301","first-page":"133","article-title":"Intrastriatal Transplantation of Mouse Bone Marrow-Derived Stem Cells Improves Motor Behavior in a Mouse Model of Parkinson\u2019s Disease","volume":"72","author":"Offen","year":"2007","journal-title":"J. Neural. Transm. Suppl."},{"key":"ref_302","doi-asserted-by":"crossref","first-page":"43","DOI":"10.1016\/j.jneuroim.2012.03.004","article-title":"Neuroprotective Effects of Human Umbilical Cord Mesenchymal Stromal Cells in an Immunocompetent Animal Model of Parkinson\u2019s Disease","volume":"246","author":"Mathieu","year":"2012","journal-title":"J. Neuroimmunol."},{"key":"ref_303","doi-asserted-by":"crossref","first-page":"394","DOI":"10.1038\/gt.2010.152","article-title":"Vegf-Expressing Human Umbilical Cord Mesenchymal Stem Cells, an Improved Therapy Strategy for Parkinson\u2019s Disease","volume":"18","author":"Xiong","year":"2011","journal-title":"Gene Ther."},{"key":"ref_304","doi-asserted-by":"crossref","first-page":"33","DOI":"10.3389\/fneur.2013.00033","article-title":"Molecular Events Underlying Parkinson\u2019s Disease\u2014An Interwoven Tapestry","volume":"4","author":"Lim","year":"2013","journal-title":"Front. Neurol."}],"container-title":["International Journal of Molecular Sciences"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/1422-0067\/17\/6\/904\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,11]],"date-time":"2025-10-11T19:25:13Z","timestamp":1760210713000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/1422-0067\/17\/6\/904"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2016,6,8]]},"references-count":304,"journal-issue":{"issue":"6","published-online":{"date-parts":[[2016,6]]}},"alternative-id":["ijms17060904"],"URL":"https:\/\/doi.org\/10.3390\/ijms17060904","relation":{},"ISSN":["1422-0067"],"issn-type":[{"value":"1422-0067","type":"electronic"}],"subject":[],"published":{"date-parts":[[2016,6,8]]}}}